

Marine biotoxins in shellfish – Yessotoxin group¹ Scientific Opinion of the Panel on Contaminants in the Food chain

(Question No EFSA-Q-2006-065D)

Adopted on 2 December 2008

SCIENTIFIC PANEL MEMBERS

Jan Alexander, Diane Benford, Andrew Cockburn, Jean-Pierre Cravedi, Eugenia Dogliotti, Alessandro Di Domenico, María Luisa Fernández-Cruz, Johanna Fink-Gremmels, Peter Fürst, Corrado Galli, Philippe Grandjean, Jadwiga Gzyl, Gerhard Heinemeyer, Niklas Johansson, Antonio Mutti, Josef Schlatter, Rolaf van Leeuwen, Carlos Van Peteghem and Philippe Verger

SUMMARY

Yessotoxin group toxins (YTXs) have been detected in filter-feeding bivalve molluscs such as oysters, mussels, scallops, and clams from various parts of the world. They are primarily produced by the marine dinoflagellate *Protoceratium reticulatum*. YTXs are polyether compounds, consisting of 11 contiguously transfused ether rings, an unsaturated side chain, and two sulphate esters. More than 90 YTXs are known, but only a few dozens have been fully identified. The most important YTXs are, 1a-homoYTX, 45-hydroxyYTX, and 45-hydroxy-1a-homoYTX. YTXs seem to be heat stable in shellfish at temperatures relevant for cooking.

The toxicological database for YTX-group toxins is limited and comprises mostly studies on their acute toxicity in mice. There are no reports on adverse effects in humans associated with YTXs. The following toxic equivalence factors (TEF) have been applied in some countries:

© European Food Safety Authority, 2008

¹ For citation purposes: Opinion of the Scientific Panel on Contaminants in the Food chain on a request from the European Commission on marine biotoxins in shellfish – yessotoxin group, *The EFSA Journal* (2008) Journal number, 907, 1-62.



YTX = 1, 1a-homoYTX = 1, 45-hydroxyYTX = 1 and 45-hydroxy-1a-homoYTX = 0.5. Because the available data (lethality of very few mice following intraperitoenal (*i.p.*) injection are not sufficient to establish robust TEF values, the Panel on Contaminants in the Food Chain (CONTAM Panel) used these TEF values as an interim measure in order to provide a best estimate of the toxicity of YTX-group toxins.

No data on the chronic effects of YTXs in animals were available, so the CONTAM Panel could not establish a tolerable daily intake (TDI). In view of the acute toxicity of YTX-group toxins, the CONTAM Panel decided to establish an acute reference dose (ARfD) based on the available animal data on acute toxicity, due to the lack of observations in humans.

Regarding the acute toxicity the mechanism of action of YTXs has not been determined with certainty, and the molecular processes underlying their toxicity are presently undetermined. The CONTAM Panel noted that four major molecular processes have been implicated in the mechanism of action of YTXs, comprising the modulation of calcium movements among different cellular compartments, the modulation of cellular adenosine 3',5'-cyclic monophosphate (cAMP) levels, the alteration of protein disposal, and apoptosis.

In a series of acute toxicity studies following oral administration no lethality and no clinical signs of toxicity were observed. This indicates that YTXs are far less toxic when given by the oral route than following *i.p.* administration for which LD_{50} values in the range of 100 to 500 μ g/kg body weight (b.w.) were observed.

Following oral administration cardiotoxicity was observed by the use of light microscopy down to a single dose of 7.5 mg/kg b.w. with a no effect level of 5 mg/kg b.w. The CONTAM Panel noted that ultrastructural changes in the myocardium have inconsistently been reported below this dose level. It also noted that these changes may be reversible, and that they were not accompanied by leakage of enzymes to serum. There were no indications of myocardial damage as identified by light microscopy. Therefore, in its derivation of an ARfD the CONTAM Panel decided to use the dose of 5 mg/kg b.w. *p.o.* as the most robust no-observed-adverse-effect level (NOAEL) for acute cardiotoxicity caused by YTXs as identified by light microscopy. However, because it is uncertain whether the ultrastructural changes should be considered as adverse or not, the CONTAM Panel decided to apply a factor of 2 in addition to the default uncertainty factor of 100 to establish an ARfD of 25 µg YTX equivalents/kg b.w.

In order to protect against the acute effects of YTX-group toxins, it is important to use a high portion size rather than a long-term average consumption in the health risk assessment of shellfish consumption. Consumption data for shellfish species across the European Union (EU) were limited, therefore the European Food Safety Authority (EFSA) requested the Member States to provide information on consumption of relevant shellfish species. Based on data provided by five Member States, the CONTAM Panel identified 400 g of shellfish meat as a large portion size to be used in the acute risk assessment of marine biotoxins.

It was noted that consumption of a 400 g portion of shellfish meat containing YTX-group toxins at the current EU limit of 1 mg YTX equivalents/kg shellfish meat would result in an



intake of 400 μ g YTXs (equivalent to 6.7 μ g/kg b.w. in a 60 kg adult). This intake is below the ARfD of 25 μ g YTX equivalents/kg b.w. (corresponding to 1500 μ g YTX equivalents per portion for a 60 kg adult) and consequently does not pose any health risk.

For the deterministic and probabilistic estimate of the exposure to YTXs the CONTAM Panel could only use the occurrence data from Norway and Italy (North Adriatic Sea). Consumption of a 400 g portion of shellfish meat containing YTXs at 315 or 799 μ g YTX equivalents/kg shellfish meat, corresponding to the 95th percentile of the concentration in Norway and Italy (North Adriatic Sea) respectively, would result in an intake of 126 or 320 μ g YTXs (corresponding to 2.1 or 5.3 μ g YTX equivalents/kg b.w. for a 60 kg adult). For both countries this estimated high intake is well below the ARfD of 25 μ g YTX equivalents/kg b.w., indicating that there is no acute health risk with respect to consumption of shellfish containing the current levels of YTXs found on the market.

The liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) results show that none of the samples from the Norwegian and Italian data set that tested negative in the mouse bioassay (MBA), exceeded a value of 3.75 mg YTX equivalents/kg shellfish meat. Therefore the CONTAM Panel concluded that a 60 kg person, consuming a portion of 400 g of shellfish currently present on the market, would not exceed an ARfD of 25 μ g/kg b.w.

The CONTAM Panel noted that, even taking into consideration all reported YTX occurrence data, thus both the MBA negative and MBA positive results, and thereby disregarding the current EU regulatory system, consumers of shellfish in Norway would not exceed the ARfD when consuming a 400 g portion of shellfish meat. In Italy (North Adriatic Sea), the ARfD would be exceeded under these circumstances by 2.9% of the consumers.

The CONTAM Panel concluded that in order for a 60 kg adult to avoid exceeding a dose of 1500 μ g YTX equivalents, corresponding to the ARfD of 25 μ g YTX equivalents/kg b.w., a 400 g portion of shellfish should not contain more than 3.75 mg YTX eq./kg shellfish meat. This level is above the current EU limit value of YTXs of 1 mg/kg shellfish flesh.

The MBA is the officially prescribed reference method in the EU for the detection of YTXgroup toxins. The CONTAM Panel noted that the method has shortcomings, e.g. it is not specific, not quantitative and has a high uncertainty at the level of the current regulatory limit.

The current EU legislation permits the replacement of the MBA, provided that the alternative methods have been validated according to an internationally recognised protocol. At this time however, none of the methods for the determination of toxins from the YTX-group have been validated by interlaboratory studies. The evidence available at this moment suggests that LC-MS/MS based methods have the greatest potential to replace the MBA. These methods also have the possibility for multi-toxin group detection/quantification. The CONTAM Panel noted that, whilst application of single laboratory validation according to recognised international guidelines to demonstrate their fitness-for-purpose can be an impetus for implementation of alternative instrumental analyses of marine biotoxins for regulatory



purposes, method performance criteria should be stipulated where possible and validation by interlaboratory trials should be the long-term objective.

Keywords: Marine biotoxins, yessotoxin (YTX), 45-hydroxyYTX, 1a-homoYTX, 45hydroxy-1a-homoYTX, shellfish, bivalve molluscs, mouse bioassay (MBA), acute reference dose (ARfD), portion size, methods of analysis, human health, risk assessment

TABLE OF CONTENTS

SCIEN	rific Panel members	. 1
SUMM	ARY	. 1
TABLE	COF CONTENTS	. 5
ВАСКО	GROUND AS PROVIDED BY THE EUROPEAN COMMISSION	. 7
1.	Legal framework	. 7
2.	The Council Directive 86/609/EEC	. 8
3.	Recognised testing methods for marine biotoxins and maximum levels	.9
4.	Joint FAO/IOC/WHO ad hoc Expert Consultation on Biotoxins in Bivalve Molluscs	
	(Oslo, September 26-30, 2004)	10
5.	Working Group Meeting to Assess the Advice from the Joint FAO/IOC/WHO ad hoc	
	Expert Consultation on Biotoxins in Bivalve Molluscs, Ottawa, Canada, April 10-12,	
	2006	12
TERMS	S OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION	13
ACKNO	OWLEDGEMENT	13
ASSESS	SMENT	14
1.	Introduction	14
2.	Chemical characteristics	14
3.	Regulatory status	16
4.	Methods of analysis	17
4.1	Supply of appropriate reference material	17
4.2	Mammalian bioassay	18
4.	2.1 Mouse bioassay (MBA)	18
4.3	Biomolecular methods	20
4.4	Chemical methods	21
4.5	Summary of methods	22
5.	Occurrence of YTX-group toxins	23
5.1	Data Collection	23
5.2	YTX-group toxin concentrations in shellfish	24
5.3	Difference between species	26
5.4	Influence of type of sampling and origin of the sample	27
5.5	Influence of processing	28
6.	Samples tested with both LC-MS/MS and mammalian bioassays	29
7.	Human consumption of shellfish	30
8.	Exposure assessment	32
8.1	Deterministic estimate of dietary exposure to YTX-group toxins	32
8.2	Probabilistic estimate of dietary exposure to YTX-group toxins	32
9.	Toxicokinetics	34
10.	Toxicity data	35
10.1	Mechanistic considerations	35
10.2	Effects in laboratory animals	38
1(0.2.1 Acute toxicity	38
	10.2.1.1 Toxicity following intraperitoneal (<i>i.p.</i>) administration	38
	10.2.1.2 Toxicity following oral administration	41
10.3	Relative potency of YTX-group toxins	43
10.4	Chronic toxicity and carcinogenicity	44
10.5	Genotoxicity	44
11.	Observations in humans	44



12.	Hazard characterisation	44
13.	Risk characterisation	46
14.	Uncertainty	47
14.1	Assessment objectives	47
14.2	Exposure scenario	48
14.3	Exposure model	48
14.4	Model input (parameters)	48
14.5	Summary of uncertainties	49
CONCI	USIONS	49
RECON	IMENDATIONS (INCL. KNOWLEDGE/DATA GAPS)	52
REFER	ENCES	53
LIST O	F ABBREVIATIONS	61



BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION

Marine biotoxins, also commonly known as shellfish toxins, are mainly produced by algae or phytoplankton.

Based on their chemical structure, the toxins have been classified into eight groups, namely, the azaspiracid (AZA), brevetoxin (BTX), cyclic imine, domoic acid (DA), okadaic acid (OA), pectenotoxin (PTX), saxitoxin (STX) and yessotoxin (YTX) groups, as agreed at the Joint FAO/IOC/WHO *ad hoc* Expert Consultation held in 2004². Two additional groups, palytoxins (PITX) and ciguatoxins (CTX), may also be considered. STX and its derivatives cause Paralytic Shellfish Poisoning (PSP), and DA causes Amnesic Shellfish Poisoning (ASP). Diarrhoeic Shellfish Poisoning (DSP) is caused by OA-group toxins (OA and dinophysis toxins (DTX)) and AZA group toxins cause Azaspiracid Shellfish Poisoning (AZP). These toxins can all accumulate in the digestive gland (hepatopancreas) of filterfeeding molluscan shellfish, such as mussels, oysters, cockles, clams and scallops, and pose a health risk to humans if contaminated shellfish are consumed. Marine biotoxin-related illness can range from headaches, vomiting and diarrhoea to neurological problems, and in extreme cases can lead to death.

To protect public health, monitoring programmes for marine biotoxins have been established in many countries, which often stipulate the use of animal models (for example, the mouse bioassay (MBA) and the rat bioassay (RBA)), for detecting the presence of marine biotoxins in shellfish tissues.

In the European Union (EU), bioassays are currently prescribed as the reference methods. Various stakeholders (regulators, animal welfare organisations, scientific organisations) have expressed their concerns about the current legislation in Europe, not only with regard to the use of large numbers of animals, involving procedures which cause significant pain and suffering even though non-animal based methods are available, but also since the scientific community argues that the animal test may not be suitable for all classes of toxins and that the state-of-the-art scientific methodology for the detection and determination of marine biotoxins is not fully reflected in current practices.

1. Legal framework

In 2004, the purported *EU Hygiene Package* of regulations, bringing together and replacing the existing hygiene regulations for the food sector previously contained in numerous individual vertical Directives was published. In Annex II Section VII Chapter V (2) to

² ftp://ftp.fao.org/es/esn/food/biotoxin_report_en.pdf



Regulation 853/2004/EC³, are established maximum levels for ASP, PSP and DSP toxins. Annex III of Commission Regulation No 2074/2005/EC⁴ of 5 December 2005 lays down the recognised testing methods for detecting marine biotoxins. Annex II Chapter II (14) to Regulation (EC) 854/2004⁵, gives the monitoring authorities in the EU Member States the mandate to examine live molluscs for the presence of marine biotoxins. The *EU Hygiene Package* came into effect on 1 January 2006.

2. The Council Directive 86/609/EEC

Council Directive 86/609/EEC⁶ makes provision for laws, regulations and administrative provisions for the protection of animals used for experimental and other scientific purposes. This includes the use of live vertebrate animals as part of testing strategies and programmes to detect identify and quantify marine biotoxins. Indeed, the scope of Article 3 of the Directive includes the use of animals for the safety testing of food, and the avoidance of illness and disease.

Directive 86/609/EEC sets out the responsibilities that Member States must discharge. As a result of this use of prescriptive language, Member States have no discretion or flexibility, and most of the provisions of the Directive must be applied in all cases. It is clear that Member States have to ensure that: the number of animals used for experimental and other scientific purposes is reduced to the justifiable minimum; that such animals are adequately cared for; and that no unnecessary or avoidable pain, suffering, distress or lasting harm are caused in the course of such animal use.

Member States may not (Article 7, 2) permit the use of live animals in procedures that may cause pain, suffering, distress or lasting harm: "if another scientifically satisfactory method of obtaining the result sought and not entailing the use of live animals is reasonably and practicably available". When animal use can be justified, Directive 86/609/EEC specifies a range of safeguards that Member States must put in place to avoid or minimise any animal suffering that may be caused. All justifiable animal use should be designed and performed to

 ³ Regulation (EC) No 853/2004 of the European Parliament and of the Council of 29 April 2004 laying down specific hygiene rules for food of animal origin. OJ L 139, 30.4.2004, p. 55–205
 ⁴ Commission Regulation (EC) No 2074/2005 of 5 December 2005 laying down implementing measures for

⁴ Commission Regulation (EC) No 2074/2005 of 5 December 2005 laying down implementing measures for certain products under Regulation (EC) No 853/2004 of the European Parliament and of the Council and for the organisation of official controls under Regulation (EC) No 854/2004 of the European Parliament and of the Council and Regulation (EC) No 882/2004 of the European Parliament and of the Council, derogating from Regulation (EC) No 852/2004 of the European Parliament and of the Council and amending Regulations (EC) No 853/2004 and (EC) No 854/2004 OJ L 338, 22.12.2005, p. 27–59.

⁵ Regulation (EC) No 854/2004 of the European Parliament and of the Council of 29 April 2004 laying down specific rules for the organisation of official controls on products of animal origin intended for human consumption. OJ L 139, 30.4.2004, p. 206–320.

⁶ Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animal used for experimental and other scientific purposes. OJ L 358, 18.12.1986, p. 1–28.



avoid unnecessary pain, suffering, distress and lasting harm (Article 8). Member States must ensure (Article 19, 1) that user establishments undertake experiments as effectively as possible, with the objective of obtaining consistent results, whilst minimising the number of animals and any suffering caused.

This latter requirement necessitates the use of minimum severity protocols, including appropriate observation schedules, and the use of the earliest humane endpoints that prevent further suffering, once it is clear that the scientific objective has been achieved, that the scientific objective cannot be achieved, or that the suffering is more than can be justified as part of the test procedure. The European Commission (EC) and Member States are also required (Article 23, 1) to encourage research into, and the development and validation of, alternative methods that do not require animals, use fewer animals, or further reduce the suffering that may be caused, whilst providing the same level of scientific information.

3. Recognised testing methods for marine biotoxins and maximum levels

Commission Regulation (EC) No. 2074/2005⁴ specifies a MBA for the determination of PSP toxins and a MBA or the RBA for lipophilic marine biotoxins. Alternative test methods can be applied if they are validated following an internationally recognised protocol and provide an equivalent level of public health protection.

Besides PSP toxins, OA, DTXs, PTXs, AZAs and YTXs, also cyclic imines, (gymnodimine, spirolides and others which are currently not regulated in the EU), all give a positive response in MBAs.

The reference method for the DA group (the causative agent of ASP) is based on high-performance liquid chromatography (HPLC).

Chapter V (2) (c) and (e) of Section VII of Annex III to Regulation (EC) No $853/2004^3$ establishes that food business operators must ensure that live bivalve molluscs placed on the market for human consumption must not contain marine biotoxins in total quantities (measured in the whole body or any part edible separately) that exceed the following limits:

- 800 micrograms per kilogram for PSP,
- 20 milligrams of DA per kilogram for ASP,
- 160 micrograms of OA equivalents⁷ per kilogram for OA, DTXs and PTXs in combination,
- 1 milligram of YTX equivalents per kilogram for YTXs,
- 160 micrograms of AZA equivalents per kilogram for AZAs.

⁷ Equivalents: the amount of toxins expressed as the amount of okadaic acid that gives the same toxic response followed intraperitoneal administration to mice. This applies similarly for the group of yessotoxins and azapiracids, respectively.



4. Joint FAO/IOC/WHO ad hoc Expert Consultation on Biotoxins in Bivalve Molluscs (Oslo, September 26-30, 2004)

Based on the available information, the Joint FAO/IOC/WHO *ad hoc* Expert Consultation suggested provisional acute reference doses $(ARfDs)^8$ for the AZA, OA, STX, DA, and YTXs, respectively (summarized in the Table 1). The Expert Consultation considered that the database for the cyclic imines, BTXs and PTXs was insufficient to establish provisional ARfDs for these three toxin groups. In addition, guidance levels were derived comparing results based on the consumption of 100 g, 250 g or 380 g shellfish meat by adults. However, the Expert Consultation noted that the standard portion of 100 g, which is occasionally used in risk assessment, is not adequate to assess an acute risk, whereas a portion of 250 g would cover 97.5% of the consumers of most countries for which data were available.

Available methods of analysis were reviewed for the 8 toxin groups and recommendations made for choice of a reference method, management of analytical results and development of standards and reference materials.

The Joint FAO/IOC/WHO *ad hoc* Expert Consultation, however, did not have sufficient time to fully evaluate epidemiological data and to assess the effects of cooking or processing for deriving the provisional guidance levels/maximum levels for several toxin groups (especially the AZA and STX groups). The Consultation encouraged Member States to generate additional toxicological data in order to perform more accurate risk assessments and to facilitate validation of toxin detection methods in shellfish.

⁸ The acute reference dose is the estimate of the amount of substance in food, normally expressed on a bodyweight basis (mg/kg or µg/kg of body weight), that can be ingested in a period of 24 hours or less without appreciable health risk to the consumer on the basis of all known facts at the time of evaluation (JMPR, 2002)



				Derived Guidance Level/ Max Level based on consumption of 100g (1), 250g (2) and 380g (3)	Limit Value currently implemented in EU legislation
AZA	0.4 (1)	10(H)	0.04 µg/kg 2.4 µg/adult ^{a)}	0.024 mg/kg SM (1) 0.0096 mg/kg SM (2) 0.0063 mg/kg SM (3)	0.16 mg/kg SM
ВТХ			N/A		0.8 mg/kg SM as Pb Tx-2
Cyclic Imines			N/A		
DA	1,000 (1)	10(H)	100 µg/kg 6 mg/adult ^{a)}	60 mg/kg SM(1) 24 mg/kg SM(2) 16 mg/kg SM(3)	20 mg/kg SM
OA	1 (1)	3(H)	0.33 µg/kg 20 µg/adult ^{a)}	0.2 mg/kg SM (1) 0.08 mg/kg SM (2) 0.05 mg/kg SM(3)	0.16 mg/kg SM
РТХ			N/A		
STX	2 (1)	3(H)	0.7 μg/kg 42 μg/adult ^{a)}	0.42 mg/kg SM(1) 0.17 mg/kg SM(2) 0.11 mg/kg SM(3)	0.8 mg/kg SM
YTX	5,000 (2)	100(A)	50 μg/kg 3 mg/adult ^{a)}	30 mg/kg SM(1) 12 mg/kg SM(2) 8 mg/kg SM(3)	1 mg/kg SM

Table	1:	Summarv	data	used	in	the	deri	vation	of the	ARfD	and	current	guidance	levels.
I unic		Summury	uutu	ubeu	111	une	avii	<i>i</i> ution	or the	mun	unu	current	Suraunee	101010.

SM = shellfish meat, LOAEL=lowest-observed-adverse-effect level, NOAEL=no-observed-adverse-effect level N/A=not available, EU=European Union

^{a)} Person with 60 kg bodyweight (b.w.)

The Joint FAO/IOC/WHO *ad hoc* Expert Consultation also indicated that there were discrepancies between different risk assessments, especially for determining methods of analysis for certain marine biotoxins and in relation to established maximum limits.



Test methods for the eight toxin groups were reviewed and recommendations for Codex purposes made. MBAs are widely used for shellfish testing but for technical and ethical reasons it is highly desirable to move to new technologies which can meet Codex requirements more adequately. Most currently available methods do not meet fully the strict criteria for Codex type II⁹ or III¹⁰ methods and have therefore not been widely used in routine shellfish monitoring. However, the recommendations made by the Expert Consultation represent the best currently available methods. Liquid chromatography-mass spectrometry (LC-MS) has much potential for multi-toxin analysis and has been recommended for consideration and recommendation by Codex. The Joint FAO/IOC/WHO *ad hoc* Expert Consultation is of the opinion that the complexity and chemical diversity of some toxin groups is such that validated quantitative methods to measure all toxins within a group will be extremely difficult. Thus the implementation of a marker compound concept and the use of functional assays should be explored.

5. Working Group Meeting to Assess the Advice from the Joint FAO/IOC/WHO ad hoc Expert Consultation on Biotoxins in Bivalve Molluscs, Ottawa, Canada, April 10-12, 2006

The working group (WG) discussed available reference methods in particular and concluded that they should be highly specific, highly reproducible, and not prone to false positives or false negatives. The methods are expected to be definitive and may well result in significant rejections of products and must therefore withstand the most robust legal and scientific scrutiny.

In considering their weaknesses and merits, the meeting noted that the various MBAs should be discussed individually since the level of performance and success differs markedly between the official method for PSP by MBA, the American Public Health Association (APHA) method for BTXs and the multiple MBA "DSP" procedures employed for the other lipophilic toxins such as OA, AZAs and others.

Recognizing that the majority of the currently available methods do not meet all Codex criteria for reference methods (Type II), the WG concluded that Codex Committee for Fish and Fishery Products (CCFFP) should consider a variety of biotoxin analytical methods. Wherever possible, reference methods should not be based on animal bioassays. Functional methods, biochemical/immunological and chemical-analytical methods currently in use, and considered to be validated according to Codex standards, should be recommended by CCFFP

⁹ A Type II method is the one designated Reference Method where Type I methods do not apply. It should be selected from Type III methods (as defined below). It should be recommended for use in cases of dispute and for calibration purposes.

¹⁰ A Type III Method is one which meets the criteria required by the Codex Committee on Methods of Analysis and Sampling for methods that may be used for control, inspection or regulatory purposes.



to the Codex Committee on Methods of Analysis and Sampling (CCMAS) for review and designation as Type II or Type III methods.

Because the Expert Consultation has offered 3 different guidance limits associated with three levels of consumption (100 g, 250 g and 380 g) for most toxin groups, it is important to determine which consumption level is appropriate for the protection of consumers.

TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION

In accordance with Art. 29 (1) (a) of Regulation (EC) No 178/2002, the Commission asks the European Food Safety Agency (EFSA) to assess the current European Union (EU) limits with regard to human health and methods of analysis for various marine biotoxins as established in the EU legislation, including new emerging toxins, in particular in the light of

- the report of the Joint FAO/IOC/WHO *ad hoc* Expert Consultation on Biotoxins in Bivalve Molluscs (Oslo, September 26-30, 2004), including the acute reference dose (ARfDs) and guidance levels proposed by the Expert Consultation,
- the conclusions of the Codex Committee for Fish and Fishery Products (CCFFP) working group held in Ottawa in April 2006,
- the publication of the report and recommendations of the joint European Centre for the Validation of Alternative Methods (ECVAM)/DG SANCO Workshop, January 2005,
- the report from the Community Reference Laboratory (CRL) Working group on Toxicology in Cesenatico October 2005,
- any other scientific information of relevance for the assessment of the risk of marine biotoxins in shellfish for human health.

ACKNOWLEDGEMENT

EFSA wishes to thank the working group members Jan Alexander, Tore Aune, Diane Benford, Luis Botana, Peter Fürst, Gerhard Heinemeyer, Philipp Hess, Sophie Krys, Angelika Preiss-Weigert, Gian Paolo Rossini, Hans van Egmond, Rolaf van Leeuwen and Philippe Verger



ASSESSMENT

1. Introduction

Yessotoxin group toxins (YTXs) have been detected in bivalve molluscs from various parts of the world. YTXs are primarily produced by the marine dinoflagellate *Protoceratium reticulatum*. Their presence in shellfish was discovered due to their acute toxicity in mice after intraperitoneal (*i.p.*) injection of lipophilic extracts. Via the oral route, however, they are much less toxic. YTXs do not induce diarrhea, and there are no reports of human intoxications caused by YTXs. The analysis of YTXs poses considerable problems due to the large number of analogues produced by the algae and their extensive metabolism in shellfish (FAO/IOC/WHO, 2004a).

2. Chemical characteristics

YTXs are polyether compounds, consisting of 11 contiguously transfused ether rings, an unsaturated side chain, and two sulphate esters (Samdal, 2005). They have been isolated from various species of shellfish, occurring in various parts of the world. YTXs are primarily produced by the marine dinoflagellate *Protoceratium reticulatum* (FAO, 2004). Isolates of *P. reticulatum* have shown a great degree of flexibility in the biosynthesic pathways of YTXs. Miles *et al.* (2005) revealed the presence of an array of more than 90 YTX analogues in one isolate of *P. reticulatum*. Only a few dozens of YTXs have been fully identified. The structures of a dozen YTXs are shown in Figure 1. Some YTX analogues can also be produced by *Lingulodinium polyedrum* (Draisci *et al.*, 1999) and the closely related *Gonyaulax* cf *spinifera* (Rhodes *et al.*, 2004).

YTXs are readily accumulated by filter feeding molluscs (FAO/IOC/WHO, 2004b). Most of the compounds found in the algae have also been found in contaminated shellfish tissues, in which they are relatively persistent and, at least initially, are concentrated in the digestive gland. The half-life for YTXs was estimated as 20 to 24 days in Blue mussels (Aasen *et al.*, 2005) and 49 days in GreenshellTM mussels (Mackenzie *et al.*, 2002). There is evidence that YTXs are metabolized in shellfish, based on observations that 45-hydroxyYTX and carboxyYTX occur in much higher proportions in shellfish as compared to *P. reticulatum*, and the proportions vary between different shellfish species (FAO/IOC/WHO, 2004b).

Although there are many different YTX analogues, they seem not to be affected by heat, since concentration procedures that use heat do not show a decrease in the amount (Alfonso *et al.*, 2007). Therefore, the group seems to be heat stable.





n=number of methyl groups in the molecule m/z=mass to charge ratio (molecular mass of the analogue diminished by 1 dalton ([M-H]⁻ ions))

Figure 1: Chemical structures of a selection of yessotoxin group toxins (YTXs) (slightly amended from Hess and Aasen, 2007).



3. Regulatory status

For the control of the YTX group toxins in the European Union (EU), Commission Regulation (EC) No 853/2004³, provides details in Annex III section VII: "Live bivalve molluscs", chapters II and IV. Chapter II: "Hygiene requirements for the production and harvesting of live bivalve molluscs. A. Requirements for production areas" states: "*Food business operators may place live molluscs collected from production areas on the market for direct human consumption only, if they meet the requirements of chapter IV*". Chapter IV: "Hygiene requirements for purification and dispatch centres. A. Requirements for purification centres" states "*Food business operators purifying live bivalve molluscs must ensure compliance with the following requirements: They must not contain marine biotoxins in total quantities (measured in the whole body or any part edible separately) that exceed the following limits: for yessotoxins, 1 milligram of yessotoxin equivalent per kilogram".*

Commission Regulation (EC) No 2074/2005⁴ provides details about the "Recognized testing" methods for detecting marine biotoxins". Annex III, Chapter III of this regulation deals with lipophylic toxin detection methods. Biological methods are to be used for the detection of these toxins, and the following details are given for YTX: "A single mouse bioassay involving acetone extraction may be used to detect yessotoxins. This assay may be supplemented, if liquid/liquid partition steps with ethyl acetate/water necessary, with dichloromethane/water to remove potential interferences. A mouse bioassay with acetone extraction followed by liquid/liquid partition with diethyl ether cannot be used to detect vessotoxins as losses of these toxins may take place during the partition step". Commission Regulation (EC) No 2074/2005⁴ also states the following concerning alternative detection methods:

"A series of methods, such as high-performance liquid chromatography with fluorescence detection, liquid chromatography, mass spectrometry, immunoassays and functional assays, such as the phosphatase inhibition assay, shall be used as alternative or supplementary to the biological testing methods, provided that either alone or combined they can detect at least the following analogues, that they are not less effective than the biological methods and that their implementation provides an equivalent level of public health protection.

- okadaic acid and dinophysistoxins: a hydrolysis step may be required to detect the presence of DTX3.
- pectenotoxins: PTX1 and PTX2.
- yessotoxins: YTX, 45-hydroxyYTX, 1a-homoYTX, and 45-hydroxy-1a-homoYTX.
- azaspiracids: AZA1, AZA2 and AZA3.

If new analogues of public health significance are discovered, they should be included in the analysis. Standards must be available before chemical analysis is possible. Total toxicity shall be calculated using conversion factors based on the toxicity data available for each toxin. The performance characteristics of these methods shall be defined after validation following an internationally agreed protocol".

Currently there is no detailed guidance on how a non-animal-based method can become an accepted alternative method, i.e. which performance criteria should be fulfilled. In addition, conversions factors have not been established. The regulation also states that "*Biological methods shall be replaced by alternative detection methods as soon as reference materials for detecting the toxins prescribed in Chapter V of Section VI of Annex III to regulation (EC) No 853/2004³ are readily available, the methods have been validated and this Chapter has been amended accordingly".*

In conclusion, the legislation stimulates the replacement of the biological methods, provided that alternative methods have been validated according to an internationally agreed protocol. Currently there are no methods for YTXs, formally validated in interlaboratory studies. The application of single laboratory validation (SLV) according to international guidelines to demonstrate fit-for-purpose of instrumental methods could offer perspectives and would need to be explored.

4. Methods of analysis

Several published methods exist for the determination of YTXs. The mouse bioassay (MBA) is still applied widely to determine YTXs, despite growing concern with respect to its use for reasons of animal welfare, its inherent variability and interference from other biotoxins which may co-exist in a sample. Some functional assays and (bio)chemical methods have also become available, although their development has been hampered due to the scarcity of reference materials, including analytical standards. None of the methods to determine YTXs have been formally validated in collaborative studies according to the harmonised protocol of ISO/IUPAC/AOAC (Horwitz, 1995).

Information on methods that are currently used or are in the process of being developed and have the potential for use in a regulatory setting is provided below. For a more general overview of other methods, the joint FAO/IOC/WHO *ad hoc* Expert Consultation on Biotoxins in Bivalve Molluscs (FAO/IOC/WHO, 2004a) and the review paper by Hess *et al.* (2006), are referred.

4.1 Supply of appropriate reference material

A certified standard for YTX is available from National Research Council Canada (NRCC). A tissue reference material for YTX has been prepared in collaboration with Marine Institute (MI), NRCC, Institute for Reference Materials and Measurements (IRMM), AgResearch (New Zealand) and Norwegian Veterinary Institute (NVI), and is currently undergoing certification studies (projected release date: end of 2009).

4.2 Mammalian bioassay

Regulation (EC) No. $2074/2005^4$ prescribes the use of the MBA for the detection of the YTXs. The test, which has not been formally validated, is described below.

4.2.1 Mouse bioassay (MBA)

Historically, the MBA has been used extensively in biotoxin monitoring and as such is incorporated into EU legislation (Commission Regulation (EC) No $2074/2005^4$ Annex III, Chapter III). The MBA was developed by Yasumoto and colleagues (1978) as an investigative tool for the determination of the causative agents responsible for a food poisoning outbreak associated with the consumption of molluscs in Japan. Essentially, for lipophilic toxins the assay uses acetone extraction of the whole flesh (or the hepatopancreas) of molluscs followed by evaporation and re-suspension of the residue in a 1% solution of Tween 60 surfactant. Mice are then exposed to the extract via *i.p.* injection and survival monitored over a 24 hour period (see Figure 2).

In efforts to improve the specificity of the assay, several modifications to the technique (generally involving an additional partitioning step) were developed (Yasumoto *et al.*, 1984; Lee *et al.*, 1987; Marcaillou-Le Baut *et al.*, 1990; Fernández *et al.*, 2002). Commission Regulation (EC) $2074/2005^4$ allows for the use of different solvents in the liquid/liquid (water) partition step including ethyl acetate, dichloromethane and diethyl ether. In the case of YTX, a dichloromethane/60% methanol extraction is required to perform a selective extraction of YTX. A positive result is defined as the death of 2 out of three mice within 6 hours of injection with an extract operationally equivalent to 25 g whole flesh (including hepatopancreas). The detectability and selectivity depends on the choice of solvents used for extraction and partitioning.

Clearly it is not ideal for a regulatory method to allow for such procedural variation, so in an effort to harmonise the methodology used within the EU, the Community Reference Laboratory for marine biotoxins (CRL-MB) has developed a standard operating procedure (SOP) based on acetone extraction with either diethyl ether or dichloromethane partitioning against water. The SOP for this method has been available at the CRL web page since 2007¹¹. A detailed extraction procedure with nearly full recovery has been reported for a selective extraction of YTX (Alfonso *et al.*, 2007).

However, several European countries among which Norway, are still applying a protocol for the MBA, where survival time is monitored over a 24 hour period, and where YTXs are not separated from other lipophylic toxins. This protocol is in contrast to the protocol where a specific methanolic extraction is applied for YTXs and where the observation period is reduced to 6 hour (see Figure 2). This is due to reluctance to use another 3 mice per sample.

¹¹ http://www.aesan.msc.es/crlmb/web/CRLMB.jsp





Figure 2: Sample preparation and extraction methods of hepatopancreas for the mouse bioassay (MBA)¹¹.



The *i.p.* LD_{50} (lethal dose – the dose required to kill half the members of a tested animal population) of YTX in mice (20 g) is approximately 100-500 µg/kg body weight (b.w.) (Ogino, 1997; Munday *et al.*, 2008). This range of *i.p.* LD_{50} dose is relatively large when compared to the okadaic acid (OA) group toxins (Aune *et al.*, 2007), adding to the uncertainty of the outcome of the MBA.

The advantages of the MBA include:

- the provision of a measure of YTXs activity;
- it does not require complex analytical equipment and the assay time is shorter than the MBA for OA. The bioassay for YTXs requires, at the current regulatory level of 1 mg/kg, an observation time of 6 hours.

The major disadvantages of the MBA include:

- it is labour intensive and cannot be readily automated;
- it requires specialised animal facilities and expertise;
- the high variability in results between laboratories due to e.g. specific animal characteristics (strain, sex, age, weight, general state of health, diet, stress);
- the large percentage of false positive results;
- it is not selective for solely the YTXs;
- requires a different extraction procedure than for the other lipophilic toxins, which further complicates the lipophilic group extraction;
- it has a high uncertainty at the level of the current regulatory limit;
- the injection volume of one mL exceeds good practice guidelines (less ≤0.5 mL) intended to minimise stress to mice;
- in many countries the use of the MBA is considered unacceptable for ethical reasons.

4.3 Biomolecular methods

YTX has been reported to decrease the adenosine 3',5'-cyclic monophosphate (cAMP) levels in human lymphocytes (Alfonso *et al.*, 2003). Although the modulation of intracellular cAMP is a rather complex process, it was suggested that this effect is mediated by activation of phosphodiesterases (PDEs) by YTX (Alfonso *et al.*, 2003). This observation has formed the basis for the development of several methods to detect YTX. Current methods based on the use of commercially available PDE preparations include the use of fluorescence microplate readers (Alfonso *et al.*, 2004), polarization fluorescence (Alfonso *et al.*, 2005), a resonant mirror biosensor (Pazos *et al.*, 2004, 2005), and surface plasmon resonance (Fonfría *et al.*, 2008). Although these methods would allow a fast and simple detection of YTX, none of the methods have been validated yet. A detailed extraction procedure with nearly full recovery has been reported for a selective extraction of YTX (Alfonso *et al.*, 2007).

The enzyme-linked immunosorbent assay (ELISA) method reported by Briggs et al. (2004) makes use of an antibody with broad cross reactivity to YTXs. This is convenient, as

knowledge about the toxicology of the different analogues is limited. A broad cross reactivity also means that samples may give a higher result, when analysed by ELISA, than with chemical methods, such as liquid chromatography-mass spectrometry (LC-MS), in which some of the analogues present may not be quantified (Samdal *et al.*, 2005). No ELISA method is fully validated yet, although several attempts are being carried out at this time. When comparing results from LC-MS and ELISA, the figures from the latter are usually higher, especially at lower levels.

The major advantages of ELISA include:

- the technique is sensitive, rapid and provides a high sample throughput;
- the equipment needed is relatively cheap;
- the technique is easy to perform, can be automated, and requires minimal training.

The major disadvantages of ELISA include:

- it is impossible to distinguish between different analogues e.g. toxin profile by the ELISA;
- it requires reference material for identification and quantification.

A two day long cell-based assay, that detects E-cadherin levels, was reported to detect YTX (Pierotti *et al.*, 2003), and this method was further shortened to a few hours with a slot blot procedure (Pierotti *et al.*, 2007), but the method is not specific for YTX, since there are interferences with azaspiracids (Ronzitti *et al.*, 2007).

4.4 Chemical methods

YTXs are polyether compounds bearing two sulfate groups and an aliphatic side chain with a conjugated diene. This chromophore allows their detection by ultraviolet (UV) detection with an absorption maximum at 230 nm (Murata *et al.*, 1987).

Due to low specificity and sensitivity of UV-detection a high-performance liquid chromatography-fluorescence detection (HPLC-FLD) method has been developed which allows a detection of 100 μ g YTXs/kg shellfish meat (Yasumoto and Takizawa, 1997). This method requires a derivatisation step, includes a time consuming clean up and is not validated.

For a specific as well as a sensitive detection of individual YTXs liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) techniques have been developed. The group of YTXs is routinely incorporated in multi-toxin methods for the detection of lipophilic biotoxins, that are used in some laboratories.

Due to the two sulfate groups YTXs are more polar than other lipophilic biotoxins. This results in different partitioning behaviour compared to other lipophilic toxins, and attention has to be paid to differences in recovery efficiencies in multitoxin clean-up procedures.



A problem for the analytical community is the lack of availability of standards. Up to now only YTX is provided as a certified calibrant (NNRC, Canada). This requires an indirect quantification of remaining YTXs assuming the same response as YTX during mass spectrometry (MS) detection.

One multi-toxin LC-MS/MS protocol that included some YTXs (YTX, 45-hydroxyYTX, 1a-homoYTX, carboxyYTX) has been subjected to a limited interlaboratory validation study (McNabb *et al.*, 2005). The limit of quantification (LOQ) for this method was 0.017 mg/kg shellfish. This is in line with reported LOQs from other studies (e.g. BIOTOX certification feasibility-study, EU-FP6-2003-Food-2A project no.: 514074) and this LOQ would be low enough for surveillance purposes.

Attempts to advance and validate methods for detection of YTXs by LC-MS/MS are being undertaken by the EU CRL-MB (Vigo, Spain) and were also performed under the auspices of the "BIOTOX" project. At the time of writing, these efforts have not led to an acceptable procedure yet.

The major advantages of LC-MS/MS include:

- information on the toxin profile of lipophilic biotoxins can be obtained without partitioning or any further clean-up steps;
- it is highly specific and sensitive;
- it can be automated.

The major disadvantages of LC-MS/MS include:

- it requires costly equipment and highly trained personnel;
- it requires reference material for identification and quantification.

4.5 Summary of methods

From the above brief summary of methods, it can be seen that, although currently described by EC legislation, the MBA has not been validated. Additionally, Council Directive 86/609/EEC⁶ states that "*Member States may not permit the use of live animals in procedures that may cause pain, suffering distress or lasting harm if another scientific satisfactory method of obtaining the result sought and not entailing the use of live animals is reasonably and practicably available*".

At this time however, none of the methods for the determination of toxins from the YTXgroup have been validated by interlaboratory studies. It is particularly important therefore, that the various methods are evaluated for their fitness for purpose.

The evidence available at this moment suggests that LC-MS/MS has the greatest potential to replace the MBA. Moreover, it is able to detect YTXs at levels below the current regulatory limit of 1 mg/kg shellfish meat. The LC-MS/MS also has the possibility for multi-toxin group



detection/quantification. However, before LC-MS/MS can be used for official purposes, validation results are needed to support their use.

5. Occurrence of YTX-group toxins

5.1 Data Collection

Following a request by the Euroepan Food Safety Authority (EFSA) for data on YTXs Germany, Italy, Norway, Portugal, Spain and United Kingdom (UK) provided data on the occurrence of YTXs in shellfish. A total of 2,881 analytical results were submitted. The number of analyses presented by the countries is relatively small and considerably different from one country to another. Table 2 shows a summary of the number of data submitted by each country including purpose of testing, analytical method applied, limit of detection (LOD) and LOQ of the methods.

Table	2:	Data	submissions	from	Member	States	for	YTX-group	toxins	in	the	period	from
2000 to	o 20	008.											

Country	Year(s) of harvesting	Number of samples	Purpose of testing ^{a)}	Method of testing	LOD (µg/kg)	LOQ (µg/kg)
Germany	2005-2006	405	pre/post-MC	LC-MS/MS	1-10 ^{b)}	-
Italy	2000-2005 2006-2008	220 254 ^{c)}	pre/post-MC	HPLC LC-MS/MS	30 30	100 100
Norway	2006-2007	1433	pre-MC	LC-MS/MS	1	10
Portugal	2005-2007	512	pre-MC	ELISA	150	- ^{d)}
Spain ^{e)}	2005-2006	17	pre-MC	HPLC, LC- MS/MS, MBA	-	-
United Kingdom	2006-2007	40	pre-MC	LC-MS/MS	66	165
Total		2881				

Pre/post-MC=pre-market/post-market control samples, LOD=limit of detection, LOQ=limit of quantification

^{a)} Pre-market control samples are samples collected at the place of origin, before or during harvesting; postmarket control samples are samples collected at the place of sale or along the distribution chain.

^{b)} Germany reports only LOD, and this is variable through the years and between different laboratories.

^{c)} The LC-MS/MS data from Italy were produced as confirmation of MBA tests, therefore their number is limited.

^{d)} ELISA analyses have only one determination threshold, reported as LOD.

^{e)} Data from Spain are statistically not relevant, therefore they were not considered in the calculations.

The submissions covered samples collected and tested during years 2005 to 2007, with the exception of a high-performance liquid chromatography (HPLC) dataset ranging between 2000 and 2005, and included pre- and post-market control samples.

Pre-market control samples (pre-MC), which are samples harvested for further processing or direct marketing as prescribed in the respective EU legislation, comprised 2477 results. Post-market control samples (post-MC), which are samples taken from the market, comprised 404 results whereas the remaining data did not come from routine shellfish monitoring. The post-

MC data (referred to samples collected at stores and supermarkets, with unknown – possibly multiple – origin) were submitted mainly from Germany (382 out of 404) while the remaining 22 were from Italy.

5.2 YTX-group toxin concentrations in shellfish

Normally the whole shellfish is consumed and therefore the occurrence data for YTXs need to be expressed in terms of whole shellfish meat. Most of the analyses were performed on whole shellfish meat. In a few samples only hepatopancreas was analysed; in this case a factor of 5 was used to convert the value to whole shellfish meat. This factor, though not representing exactly all individual molluscs, is considered to represent a good approximation.

Most of the samples reported values for four YTXs: YTX, 45-hydroxyYTX, 1a-homoYTX and 45-hydroxy-1a-homoYTX. The values were determined separately for any single analogue or in a cumulative way, depending on the analytical technique applied. Some samples, but not all, were analysed also for carboxyYTX and carboxy-1a-homoYTX. For these two analogues the animal toxicity studies are very limited and suggest a much lower toxicity than the above mentioned four variants, therefore it was decided to disregard the two carboxy-analogues in the exposure analysis.

The analysis was accordingly focused on the four analogues mentioned in Commission Regulation (EC) No 2074/2005⁴: YTX, 45-hydroxyYTX, 1a-homoYTX and 45-hydroxy-1a-homoYTX.

The conversion to YTX equivalents (YTX eq.) was performed applying a factor of 0.5 for 45hydroxy-1a-homoYTX and a factor of 1 for all the others (see chapter 10.3).

A total of 2864 samples were initially considered for the descriptive statistical calculations. Since the development of analytical methods in the marine biotoxins area is continuous, different (and not directly comparable) methods had been used in different countries and/or at different periods of time. The submitted data were obtained with 4 different analytical methods:

- 1. ELISA with a LOD of 150 μ g/kg
- 2. HPLC with a LOD of 30 μ g/kg
- 3. LC-MS/MS with higher instrument sensitivity having a LOD variable in the range 1- $10 \ \mu g/kg$
- 4. LC-MS/MS with lower instrument sensitivity having a LOD ranging between 30 and 66 μg/kg (with most analyses at 30 μg/kg)

For the imputation of values reported below LOD or below LOQ the "bounding" approach was adopted, which consists of forcing values at the boundaries of their possible variability. The lower bound is obtained by assigning a value of zero (minimum possible value) to all the samples reported as <LOD or <LOQ. The upper bound is obtained by assigning the value of

LOD to values reported as <LOD and LOQ to values reported as <LOQ (maximum possible value).

Table 3 provides an overview of the descriptive statistics of the data grouped by analytical method and country. Samples without reported values were assigned to upper- and lower bound. When the statistical descriptors in the two approaches are the same the value is given, otherwise the lower-upper bound range is reported.

Analytical		Median	Mean	P95	Maximum	% of samples	% of values
method/Country	N	µg Y	TX eq./kg s	not quantified	eq./kg shellfish meat		
ELISA							
Portugal 2005-07	512	≤150	174-260	737	1599	57.4	2.3
HPLC							
Italy 2000-05	220	705	1108-1113	3354	9620	14.5	40.0
LC-MS/MS higher instrument sensitivity							
Germany 2005-07	405	≤5	5-10	33	240	89.4	0.0
Norway 2006-07	1433	17	129	567	3707	34.8	2.8
LC-MS/MS lower instrument sensitivity							
Italy 2006-08	254	119	619-646	2328	8558	42.9	16.1
UK 2006-07	40	≤165	9-137	9-165	188	95.0	0.0
					1		

Table 3: Statistics of relevant data of YTX-group toxins in shellfish sampled in 2000 to 2008 provided by Member States.

N=number of samples, P95=95th percentile, YTX eq.=YTX equivalents

For most of the data no information is available on measurement uncertainty. When a range is given it indicates the difference between using the lower or upper bound for samples below the LOD or LOQ. The upper bound is performed substituting "<LOD" with LOD value and "<LOQ" with LOQ value; LOD and LOQ are those defined for the specific single analysis.

The concentration of YTXs in the current collection of shellfish samples from European countries ranges from "*not detected*" to 9620 µg/kg shellfish meat.

Particularly high values were reported in the Italian dataset, both HPLC and LC-MS/MS. Marine biotoxins are known to show a non-homogeneous distribution in terms of time and geographical location (Ciminiello *et al.*, 1999). In this case it has to be emphasised that the dataset from Italy does not represent the whole country, but is focused on an area – the north Adriatic Sea – affected by a significant YTX contamination in recent years. This hot spot therefore represents a worst case scenario for the occurrence of YTX along the European coasts.

The percentage of samples with a non-quantified value varies to a large extent, depending on country and year of harvesting, ranging from 14.5% for Italy in the years 2000-2005 to 95.0% for UK in the years 2006-2007, with an average of 45.6% for all 2864 analysed data. The very



large proportion of non detected or non quantified values makes the UK dataset very problematic for exposure calculations, since the median, mean and 95th percentile are strongly influenced by the upper or lower bound assumption. Consequently it was decided to exclude these data from further use.

The proportion of samples exceeding the regulatory limit of 1000 μ g/kg has also been reported. It varies among countries between 0% (Germany and UK) and 40% (Italy, 2000-2005 HPLC).

The overall differences in selectivity of the analytical methods, objective of the investigation, time of sample collection (pre- or post-market) and number of samples reported, makes it difficult to compare countries and to consider a single dataset as representative for the respective country. Nevertheless two rather homogeneous data sets were identified being suitable for exposure assessment:

- Group 1. A set of 1838 data from Germany and Norway based on LC-MS/MS analysis with higher instrument sensitivity; 46.8% of the samples in this dataset had levels of YTXs below the LOD or LOQ;
- Group 2. A set of 254 data from Italy (North Adriatic Sea) based on LC-MS/MS analysis with lower instrument sensitivity; 42.9% of the samples in this dataset had levels of YTXs below the LOD or LOQ.

Due to the different sensitivity of the analytical methods these datasets will be dealt with separately. Moreover, as can be seen in chapter 6, they also represent two different occurrence scenarios: Group 1 a low to medium contamination, Group 2 a "hot spot" (high occurrence).

For these two data upper- and lower bound values are calculated for each statistical descriptor and these values are reported as a single value when they are the same or as a range when they are different.

5.3 Difference between species

Mussels were the predominant shellfish product tested, accounting for 1779 samples of the 2092 (85%). A number of 134 samples had no species identification (6.4%). Nevertheless a few data from other species were reported and their statistical descriptors are summarised in Table 4.

Spacios	N	Total co	oncentration ug YTX eq. /k	% of samples	% of values >1000 µg		
Species	N	Median	Mean	P95	Maximum reported	not quantified	shellfish meat
Group1							
Clams ^{b)}	36	n.a.	n.a.	n.a.	n.a.	100	0
Cockles ^{\$ b)}	4	n.a.	n.a.	n.a.	n.a.	100	0
Crabs*	19	15	28-30	133	138	36.8	0 #
Mussels	1552	12-13	119-120	548	3707	48.0	2.6
Others	134	≤5	5-10	34	240	91.8	0
Oysters	47	≤5	15-18	99	321	85.1	0
Scallops ^{b)}	46	n.a.	n.a.	n.a.	n.a.	100	0
Group2							
Clams ^{b)}	22	n.a.	n.a.	n.a.	n.a.	100	0
Gastropods ^{\$,* a)}	1	n.a.	764	n.a.	n.a.	n.a.	n.a.
Mussels	227	196	689-715	2567	8558	37.9	18.1
Oysters ^{\$ b)}	4	n.a.	n.a.	n.a.	n.a.	100	0
ALL	2092						

Table 4	: Statistical	descriptors	for YTX-group	toxins occurrence	in	different s	hellfish
			- 0				

N=number of samples, YTX eq.=YTX equivalents, P95=95th percentile, n.a.= not applicable

* Currently not regulated

[#]Based on brown meat and not on whole flesh

^{\$}Samples are not enough to allow statistical calculations

^{a)} Only one sample: in the column "mean" the value is reported; no statistical calculation possible.

^{b)} Since no numerical result was reported, calculation for these values has not been performed.

When a range is given it indicates the difference between using the lower or upper bound for samples below the LOD or LOQ. The upper bound is performed substituting "<LOD" with LOD value and "<LOQ" with LOQ value; LOD and LOQ are those defined for the specific single analysis.

YTXs were not detected in clams and cockles. In scallops they were detected in two samples out of 46, but at a level below the LOQ. A low level of YTXs was registered in crabs (currently not regulated) and oysters. A somewhat higher presence was recorded in mussels, with median and mean values well below the regulatory limit. The 95th percentile value was below the regulatory limit for Group 1, but much higher than the limit for Group 2.

The samples exceeding the regulatory limit of 1000 μ g/kg only referred to mussels, with a proportion of 2.6% of the data in Group 1 and 18.1% of the data in Group 2 above the limit value. It is emphasised that these data are monitoring samples of which some were excluded from the market due to high test results. Consequently they offer a picture of the harvest, but not of the products offered for sale.

5.4 Influence of type of sampling and origin of the sample

The Group 1 and Group 2 datasets contained samples from local monitoring programmes including samples from both pre- and post-MC. The comparison between pre- and post-

market data in the two groups is shown in Table 5. These data were all measured by means of LC-MS/MS and represent results from 2005 to 2008.

Data	Ν	Total co	oncentration ug YTX eq./kg	% of samples	% of values >1000 µg		
groups	N	Median	Mean	P95	Maximum	not quantified	shellfish meat
Group1	1838						
pre	1456	16	127-128	561	3707	45.5	2.7
post	382	≦5	5-10	35	240	88.7	0
Group2	254						
pre	232	180	664-691	2525	8558	40.5	17.2
post	22	≤30	144-175	916	2011	81.8	4.5

Table 5: Statistics of LC-MS/MS data of YTX-group toxins in shellfish in Group 1 and Group 2 datasets.

N=number of samples, P95=95th percentile, YTX eq.=YTX equivalents

When a range is given it indicates the difference between using the lower or upper bound for samples below the LOD or LOQ. The upper bound is performed substituting "<LOD" with LOD value and "<LOQ" with LOQ value; LOD and LOQ are those defined for the specific single analysis.

In Group 2 (Italy, North Adriatic Sea) the data on pre- and post-market samples refer to the same geographical area and clearly show a lower contamination in the post market samples as an effect of the screening control at the production sites. Nevertheless, 1 out of 22 post market samples has a concentration (2011 μ g YTX eq./kg) above the limit value.

The samples in Group 1 are not homogeneously distributed with respect to pre-MC and post-MC: all the 1433 samples from Norway are pre-market samples, whereas 382 samples from Germany are post-market samples (origin unknown), and only 23 are pre-market samples from local production. Nevertheless, also this group shows lower levels of YTX contamination in post market samples.

The comparison of the two datasets of pre-MC samples (which related to local production) confirms the existence of significant differences in occurrence between different geographical areas.

5.5 Influence of processing

There is no information on the effect of processing (e.g. cooking) on the levels of YTXs in shellfish. However, it can be assumed that, as for other lipophilic marine biotoxins, cooking may lead to an increase in concentration of YTXs in shellfish flesh due to water loss.



6. Samples tested with both LC-MS/MS and mammalian bioassays

Not all of the 2092 samples reported in Group 1 and Group 2 were tested with both LC-MS/MS and MBA. Only for 520 samples, 269 from Norway and 251 from Italy (North Adriatic Sea) results from both LC-MS/MS and MBA were reported. Table 6 summarises the statistical descriptors for each of the subsets with respectively positive and negative MBA.

Table	6:	Concentrations	of	YTX-group	toxins	measured	by	LC-MS/MS	in	samples
compai	rativ	ely tested by ME	BA.							

Mouse Piecesou	N	Tot μg	al concentra YTX eq./kg s	% of samples	% of values >1,000 µg		
Mouse Bloassay	Z	Median	Mean	P95	Maximum	not quantified	shellfish meat
Norway	269						
Positive	55	16	159	599	3004	43.6	1.8
Negative	214	≤10	78-79	315	3707	52.8	0.9
Italy	251						
(North Adriatic Sea)	251						
Positive	75	959	1636-1646	5750	8558	13.3	49.3
Negative	176	≤100	191-225	799	1647	58.0	2.3

N=number of samples, P95=95th percentile, YTX eq.=YTX equivalents

When a range is given it indicates the difference between using the lower or upper bound for samples below the LOD or LOQ. The upper bound is performed substituting "<LOD" with LOD value and "<LOQ" with LOQ value; LOD and LOQ are those defined for the specific single analysis.

The percentage of samples testing negative in the MBA but having an LC-MS/MS value higher than the regulatory limit (1000 μ g YTX eq./kg shellfish meat) was 0.9% for Norway and 2.3% for Italy (North Adriatic Sea). In the dataset from Italy 13.3% of the samples testing positive in the MBA had a value below the LOD or LOQ. For the Norwegian data 43.6% of the samples testing positive in MBA had an LC-MS/MS value below LOD or LOQ. This high proportion of false positive results indicates a contribution of other lipophilic toxins, such as OA-, AZA-, PTX- or cyclic imine group toxins, or combinations thereof.Norway is still applying a protocol for the MBA with an extraction procedure that does not separate YTXs from other lipophilic toxins. This is in contrast with the protocol applied in Italy that includes an additional methanol extraction for YTXs.

It can be assumed that in countries using mammalian bioassay as screening method all bivalve molluscs showing a negative response in mammalian bioassays reach the market and will thus be consumed. From this perspective, the dietary intake of YTXs (see chapter 8) may be estimated based on the LC-MS/MS data for those samples that tested negative in the MBA, when the MBA was used as the screening method. This approach is applicable for the Italian situation. The Panel recognised, however, that in Norway the screening of shellfish for YTXs is performed with both the MBA and LC-MS/MS, and that the decision for placing shellfish on the market is always based on the LC-MS/MS results. This implies that in Norway no shellfish will reach the market with concentrations of YTXs above the current limit value of

 $1000 \ \mu g \ YTX \ eq./kg \ shell fish \ meat.$ Nevertheless, the Panel decided to use the negative MBA data from the Norwegian dataset (See Table 6) as a representation of other European countries with low to medium YTX contamination and applying the MBA as screening method.

7. Human consumption of shellfish

Limited consumption data were available for individual shellfish species across the EU. The EFSA Concise European Food Consumption Database does not yet provide sufficient information since there is no differentiation between meal sizes for fish and other seafood. Therefore, EFSA requested the Member States to provide information on shellfish consumption. Data were submitted by France, Germany, Italy, The Netherlands and UK. A compilation of the data received is presented in Table 7. The mean portion sizes for consumers only ranged between 10 g (France, bivalve molluscs) and 136 g (The Netherlands). The data from Germany, Italy and UK are within this range.

The German national food consumption survey performed by a weighing protocol in the late 1980s indicates a minimum meal size of mussels of 2 g (mainly as an ingredient in dishes), a median of 63 g, a mean of 107 g and a 95th percentile of 400 g among mussel consumers. The maximum portion size reported in this study was 1,500 g (Adolf *et al.*, 1995). The French Calipso study differentiated mussels and bivalve molluscs (Leblanc, 2006). The maximum portions for mussels (245 g) and all bivalve molluscs (415 g) varied, whereas the mean portions were similar. A survey reported by the United Kingdom indicates a mean shellfish meal size of 114 g and a maximum of 239 g (Henderson *et al.*, 2002). A Dutch study reported a mean portion size of 136 g of shellfish and a maximum of 480 g. These data are for consumers only (Kistemaker *et al.*, 1998). The surveys show a large variation in the percentage of the populations consuming shellfish and it is unclear whether the data are related to cooked or uncooked shellfish.



Table 7:	Shellfish	eating	habits	in	France,	Italy,	The	Netherlands,	the	UK,	and	Germany,
based on	national fo	ood con	sumpti	on s	surveys.							

		Number of consumers N (%)	Number of eating occasions for consumers/year	Mean portion weight (g)	95th percentile (g)	Maximum portion weight (g)	Maximum frequency
France	INCA	218/1985					
(7 days) France (FFQ)	1999 CALIPSO 2004	(11%)	N/A	10			N/A
	(bivalve	962/997					
	molluscs)	(96%)	N/A	32	94	415	N/A
France (FFQ)	CALIPSO 2004 (mussels)	862/997 (86%)	N/A	22	70	245	N/A
Italy (7 days)	INN-CA	212/1,981					
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	1994-96	(11%)	47	83		1,000	4/week
Germany	NVS	150/23,239					
(7 days) UK (7 days)	1985-88 NDNS	(0.6%) 212/1,631	171	107	400	1,500	3/week
, <i>,</i> ,	2000-01	(13%)	51	114		239	4/week
The Netherlands	DNFCS	47/4,285					
(2 days)	1997-98	(1.1%)	39	136	465	480	N/A

FFQ = food frequency questionnaire, 7 days = 7 day diary record, N/A = not available

INCA = Enquete Individuelle et Nationale sur les Consommations Alimentaires (Volatier, 2000).

CALIPSO = Fish and seafood consumption study and biomarker of exposure to trace elements, pollutants and omega 3 (Leblanc *et al.*, 2006)

INN-CA = Nationwide Nutritional Survey of Food Behaviour (Turrini et al., 2001)

NVS = Nationale Verzehrsstudie (Adolf *et al.*, 1995)

NDNS = National Diet and Nutrition Survey (Henderson et al., 2002)

DNFCS = Dutch National Food Consumption Survey (Kistemaker et al., 1998)

Because YTXs have acute toxic effects, it is important to identify a high portion size rather than a long term average consumption in order to protect the health of the consumer. In the studies presented in the table above, the maximum reported sizes are in the range of 239 to 1,500 g. The CONTAM Panel noted the highest portion sizes of 1,000 g and 1,500 g, and considered it likely that the shells were included in these weight estimates. Therefore, the Panel considered the 95th percentile as a more realistic estimate of the portion size for high consumers. As shown in Table 7 the 95th percentile values range from 70-465 g, the Panel chose the figure of 400 g to be used as a high portion size in acute exposure assessments. This is in good agreement with the report of the Joint FAO/IOC/WHO *ad hoc* expert consultation on marine biotoxins (FAO/IOC/WHO, 2004a) where 380 g was reported as the highest 97.5th percentile portion size for consumers only.



8. Exposure assessment

8.1 Deterministic estimate of dietary exposure to YTX-group toxins

Based on the assumption that products tested negative in the MBA, and hence fulfil the screening criteria, reach the market, and considering the North Adriatic and Norwegian scenarios shown in Table 6 and Table 7, the dietary exposure can be estimated as in Table 8.

Table 8: Deterministic intake estimate of YTX-group toxins, based on data from Norway and Italy (North Adriatic Sea), from samples tested negative in the MBA.

	Norway	Italy	
		North Adriatic Sea	
P95 (concentration of samples tested negative in the MBA)	315 µg/kg whole shellfish meat	799 µg/kg whole shellfish meat	
Exposure by eating a 400 g	125 µg YTX eq. per person	320 µg YTX eq. per person	
portion	(2.1 µg/kg b.w.)	(5.3 µg/kg b.w.)	
Exposure by eating a 400 g			
portion containing YTXs at EU	400 µg YTX e	eq. per person	
limit of 1000 µg/kg whole	(6.7 µg/kg b.w.)		
shellfish meat			

P95=95th percentile, YTX eq.=YTX equivalents, b.w.=body weight, MBA=Mouse bioassay, EU= European Union

These results are conservative, but not unrealistic estimates of high level YTX dietary exposure in two European countries.

8.2 Probabilistic estimate of dietary exposure to YTX-group toxins

A probabilistic estimate of dietary exposure to YTXs has been performed by a Monte Carlo simulation using the distributions of both the occurrence data (summarised in Table 6) and the data on the consumption of shellfish. Compared to the deterministic estimate the probabilistic exposure estimate provides information on the probability to exceed a specific exposure level. Because a person eating shellfish will not eat the same portion size containing the same level of toxins each time, the probabilistic calculation includes all the combinations of all different occurrence and consumption data.

For the probabilistic estimate the same concentration data obtained by the LC-MS/MS measurements of the samples tested negative in the MBA (Table 6) were used¹². It can be

¹² All samples with quantified levels (>LOQ) of YTX -group toxins were submitted to the best fit approach of the @RISK tool, to obtain an optimal adaptation of the distribution function, as described in the following:

Italy, Risklognormal (491,66; 415,81; RiskShift (-27,234); RiskTruncate(100;)), n=74, (42% of all data) Norway, RiskLognorm (153,68; 342,95; RiskShift (8,465); RiskTruncate(10;)), n=101 (48% of all data)

The distribution function was truncated at the respective LOQs as shown in the formula. The values below LOQ/LOD were characterised as follows: a random assignment of the values was performed using a discrete distribution [RiskDiscrete ($\{0;1\};\% < LOQ; \% > LOQ$) for Italy, and Norway, to reflect the number of samples at or below the LOQ and the number of samples with quantified toxin concentrations. This means that the ratio of



assumed that all bivalve molluses showing a negative response in MBA will reach the market and will thus be consumed. From this perspective, it is not unrealistic to estimate the dietary intake of YTXs based on the LC-MS/MS data for those samples that tested negative in the MBA.

Because insufficient information is available on the distribution of portion sizes, the CONTAM Panel decided to use a triangular distribution as a simple and pragmatic approach. A triangular distribution is characterised by three values, the minimum, the most probable and the maximum. In the case of shellfish consumption a value of 0 g was used as a minimum. From the range of 10 g to 136 g reported as mean consumption figures in Table 7 the Panel chose a value of 100 g to be used as "most probable" value, although there is no evidence that it is the most frequently consumed portion. The better-documented large portion size of 400 g (see chapter 7) was used to represent the maximum.

Due to differences in the occurrence data from Italy and Norway the evaluation of dietary exposure to YTXs was performed separately for these two datasets, taking also into account the different methods applied and different values for the reported LODs and LOQs (see Table 2).





non-quantified/quantified samples was adjusted to the different data. These latter data were simulated using a uniform distribution function [*RiskUniform* (0;LOQ)].

The resulting probabilistic dietary exposure distribution, illustrating the probability of exceeding a specific intake level of YTX equivalents when consuming a single portion of shellfish is presented in Figure 3. Due to differences in the available occurrence data the dietary exposure for Italy and Norway differs considerably. For Italy the probabilistic exposure distribution has a median of approximately 14 μ g YTX equivalents per portion, a mean of approximately 40 μ g YTX equivalents per portion, and a 95th percentile of 158 μ g YTX equivalents per portion. The exposure distribution based on the Norwegian data has a median value of 1.9 μ g YTX equivalents, a mean of 15.5 μ g YTX equivalents, and a 95th percentile of approximately 88 μ g of YTX equivalents per portion.

Based on the results of probabilistic dietary exposure distribution it is calculated that in Italy (North Adriatic Sea) the probability to exceed the deterministic dietary exposure of 400 μ g YTX equivalents per person, corresponding to a consumption of a 400 g portion containing YTXs at the level of the current EU limit value, is 0.5%.

9. Toxicokinetics

The information on toxicokinetics of YTXs is scarce. However, in a kinetic experiment, known amounts of YTX were administered orally to mice. Urine samples were taken at hourly intervals, and the mice were killed after 6 hours and tissues were collected. Only trace amounts of YTX were found in blood, urine, and tissues. Most of the toxin was recovered from the lower intestine and faeces (Munday *et al.*, 2008).

From an ongoing study in Norway (Aasen et al., 2008) NMRI female mice received YTX by gavage at doses of 1 and 5 mg/kg b.w., three mice per dose. Tissue samples taken at 24 hrs from stomach, small and large intestines, liver, kidney, lung, heart, thymus, spleen, brain and blood were examined for YTX by LC-MS/MS. Five mice received vehicle only, as control animals. At the highest YTX dose, the highest toxin levels were found in the ileum (242 µg/kg fresh weight), followed by colon (108 µg/kg fresh weight), jejunum (98 µg/kg fresh weight) and duodenum (74 µg/kg fresh weight). In the kidneys and spleen the levels were 41 μ g/kg and 34 μ g/kg, respectively. In the heart the level was only 9 μ g/kg. The YTX level in the blood was estimated approximately at 8 ng/g (by ELISA). YTX in blood was almost nondetectable by LC-MS. At the YTX dose of 1 mg/kg, the levels detected were considerably lower, a maximum of about 58 µg/kg in the colon and 46 µg/kg in the ileum, and about 30 µg/kg in jejunum and duodenum. The levels in kidneys and spleen were about 10 µg/kg, while in the heart only 3 µg/kg was detected. The level of YTX in blood (by ELISA) was approximately 4 ng/g. When comparing results from LC-MS and ELISA in other organs, the figures from the latter were usually higher, especially at low levels. No YTX was found in the control animals.

In a recent study by Tubaro *et al.* (2008a), blood samples were taken from mice (n=3) 24 hours after the last gavage of YTX at 1 mg/kg/day for 7 consecutive days. The plasma concentration of YTX was analysed using direct ELISA. After correction for recovery, a



mean blood concentration of about 6 ng/mL, corresponding to 5 nM, was reported (Tubaro *et al.*, 2008a).

No data on bio-transformation of YTX in experimental animals were identified.

10. Toxicity data

10.1 Mechanistic considerations

The mechanism of action of YTXs has not been determined with certainty, and the molecular processes underlying their toxicity are presently undetermined. The molecular activity of YTX has originally been investigated with reference to earlier observations that associated this class of toxins with OA group toxins, but the finding that YTX inhibits type 2A serine/threonine phosphoprotein phosphatase only at inhibitory concentrations (IC₅₀ = 0.36 μ g/mL)¹³ that are four orders of magnitude higher than the effective doses of OA (Ogino *et al.*, 1997), has provided the molecular basis to distinguish YTXs from OA and other dinophysis toxins (Ogino *et al.*, 1997).

Four major molecular processes have been implicated in the mechanism of action of YTXs, comprising the modulation of calcium movements among different cellular compartments, the modulation of cellular cAMP levels, the alteration of protein disposal, and apoptosis. Very recently it was shown that YTX at 10^{-7} - 10^{-6} molar concentrations inhibited beating frequency in cardiomyocytes *in vitro* (Dell'Ovo *et al.*, 2008). Table 9 summarises the different molecular responses reported for YTX in different cell systems.

 $^{^{13}}$ The concentration of a substance that reduces the effect by 50%.



Effects	Cell type and species	Concentration (M)	Time frame	Reference
Phosphodi-esterase activation	Human lymphocytes, rat mast cells, neurons	10 ⁻⁶	seconds/minutes	Alfonso <i>et al</i> ., 2003, 2004, 2005; Pazos <i>et al</i> ., 2004, 2005, 2006
Modulation of calcium movements	Lymphocytes (human)	10 ⁻⁶	seconds/minutes	De la Rosa <i>et al.</i> , 2001
at several levels	Immunocytes (mussel)	10 ⁻⁷	minutes/hours	Malagoli <i>et al</i> ., 2006a
	MH1C1 (rat)	10 ⁻⁷	seconds/minutes	Bianchi <i>et al</i> ., 2004
	Primary neuronal cells (rat)	10 ⁻⁸	minutes/hours	Pérez-Gómez et al., 2006
Calcium –dependent cAMP decrease	Lymphocytes (human)	10 ⁻⁶	seconds/minutes	Alfonso <i>et al.</i> , 2003
Calcium –dependent cGMP decrease	Lymphocytes (human), rat mast cells	10 ⁻⁶	seconds/minutes	Alfonso <i>et al.</i> , 2008
Altered protein disposal	MCF-7 (human) and MDCK (dog)	10 ⁻⁹	hours	Pierotti <i>et al.</i> , 2003; Ronzitti <i>et al.</i> , 2004; Callegari and Rossini, 2008
	IPLB-LdFB (insect) and 3T3 (mouse)	10 ⁻⁸	hours	Malagoli <i>et al</i> ., 2006b
Apoptosis and cell death	Glioma cells (rat)	10 ⁻⁶	days	Ogino <i>et al</i> ., 1997
	HeLa S ₃ (human)	10 ⁻¹⁰	days	Malaguti and Rossini, 2001; Malaguti <i>et al</i> ., 2002
	BE(2)-M17 (human)	10 ⁻⁸	days	Leira <i>et al</i> ., 2002
	Myoblasts (mouse and rat)	10 ⁻⁷	days	Suárez Korsnes <i>et al.</i> , 2006a; 2006b; 2007
	Primary neuronal cells (rat)	10 ⁻⁸	days	Pérez-Gómez et al., 2006
	IPLB-LdFB (insect) and 3T3 (mouse)	10 ⁻⁸	days	Malagoli <i>et al.</i> , 2006b
	Primary cultures cardiomyocytes (rat)	10 ⁻⁸	days	Dell'Ovo et al., 2008
Change in cell shape	Immunocytes (mussel)	10 ⁻⁷	minutes/hours	Malagoli and Ottaviani, 2004

Table 9: Molecular responses induced by yessotoxin (YTX) in cultured cells.



It has been shown that YTX (10^{-6} M) induces the influx of extracellular Ca²⁺ into lymphocytes, and that both L-type voltage-activated and depletion-activated calcium channels could be activated by YTX (De la Rosa *et al.*, 2001). The effect of YTX on L-type voltage-activated calcium channels has been confirmed (Malagoli and Ottaviani, 2004; Malagoli *et al.*, 2006a; Pérez-Gómez *et al.*, 2006), but intracellular calcium does not represent the initial event leading to late cell death in YTX-treated cells (Pérez-Gómez *et al.*, 2006; Dell'Ovo *et al.*, 2008).

The permeability transition pore (PTP) is another component affected by YTX (Bianchi *et al.*, 2004). YTX (10^{-7} - 10^{-6} M) induces membrane depolarization in isolated rat liver mitochondria when micromolar calcium concentrations are present in the incubation buffer, indicating that the toxin could induce calcium uptake by mitochondria (Bianchi *et al.*, 2004).

Incubation of human lymphocytes with YTX (10^{-7} - 10^{-6} M) induced a decrease in cellular cAMP levels, an effect that could be due to an increase in 3',5'-cyclic nucleotide 5'-nucleotidohydrolase (PDE) activity in the cells. Indeed, Alfonso *et al.* (2003) reported that YTX increased cAMP metabolism. The fact that the effect of YTX on PDE is strictly calcium-dependent, suggests that changes in intracellular calcium could be involved in the response. It has also been reported that YTXs affect some other phosphodiesterases (Alfonso *et al.*, 2004, 2005; Pazos *et al.*, 2004, 2005, 2006). A change in the intracellular cAMP levels, however, was not found in primary cultures of cardiomyocytes, where 10 nM YTX induced cell death (Dell'Ovo *et al.*, 2008).

The alteration of protein disposal is another molecular response induced by YTX. The toxin determines the accumulation of a fragment of the cell-cell adhesion protein E-cadherin in human breast cancer cells (Pierotti *et al.*, 2003). The effect in epithelial cells is induced by very low YTX concentrations $(10^{-10}-10^{-9} \text{ M})$ (Ronzitti *et al.*, 2004). YTX does not enhance E-cadherin degradation *per se*, but interferes with its normal disposal, preventing endocytosis and complete degradation of the protein fragment produced after the initial proteolytic attacks (Callegari and Rossini, 2008). Altered cell adhesion is not detected in the first phases of YTX-induced inhibition of E-cadherin endocytosis and disposal (Ronzitti *et al.*, 2004; Ronzitti and Rossini, 2008), but prolonged cell exposure to YTX results in the disruption of the E-cadherin-catenin system, altered cell-cell adhesion and inhibition of cell proliferation (Ronzitti *et al.*, 2004). Such effects are also seen *in vivo* (see chapter 10.2).

Cytotoxicity and cell detachment from culture dishes were the most prominent effects originally observed upon treating cultured rat glioma cells with YTX (Ogino *et al.*, 1997). The potent toxic effect of YTX has been later confirmed in other cellular systems (Malaguti and Rossini, 2001; Leira *et al.*, 2002; Malaguti *et al.*, 2002; Ronzitti *et al.*, 2004), and evidence has been obtained that the toxin triggers cell death through apoptosis (Malaguti and Rossini, 2001; Leira *et al.*, 2002; Malaguti *et al.*, 2002; Malaguti *et al.*, 2006b; Pérez-Gómez *et al.*, 2006; Suárez Korsnes *et al.*, 2006a, 2006b, 2007). Experimental data indicate that YTX activates the intrinsic pathway of apoptosis (Malaguti and Rossini, 2001; Leira *et al.*, 2002;



Malaguti *et al.*, 2002; Suárez Korsnes *et al.*, 2006a, 2006b). Furthermore, it has been shown that YTX ($10^{-7} - 10^{-6}$ M) causes impairment in the beating activity as well as a reduction in the viability of primary cultures of rat cardiomyocytes, in a Ca²⁺- and cAMP-independent way (Dell'Ovo *et al.*, 2008).

Available knowledge and experimental data regarding the effective doses and time-frames of YTX action, as well as the different effects found in distinct cellular systems, have been explained in two ways. One hypothesis is that the low concentrations needed are due to down- or up-regulation of molecular components such as PDE, which in turn could lead to the observed long term effects (Alfonso and Alfonso, 2008). Other authors, however, proposed that YTX has two major mechanisms of action, involving high affinity ($K_D \approx 10^{-10}$ M) and low affinity ($K_D \approx 10^{-7}$ M) receptors, respectively (Ferrari *et al.*, 2004; Rossini *et al.*, 2006).

Further studies are needed to obtain a better understanding of the molecular mechanisms underlying the toxicity of YTXs.

10.2 Effects in laboratory animals

10.2.1 Acute toxicity

10.2.1.1 Toxicity following intraperitoneal (*i.p.*) administration

Terao *et al.* (1990) used male ICR mice (23-25 g) in a study of acute toxicity of YTX. Mice receiving *i.p.* injections of YTX at 300 µg/kg or above showed normal behaviour for the first few hours. Then, suddenly, dyspnoea set in and they died. According to Tubaro *et al.* (2003), CD-1 female mice treated with YTX are restless, and at lethal doses, dyspnoea and jumping were recorded before death. At very high doses, the mice died within 30-50 minutes after injection, while they survived for ten hours or more at doses close to the LD₅₀ (512 µg/kg). Similar symptoms were described by Aune *et al.* (2002), using female NMRI mice, weighing 15-19 g. Doses used were 100, 250, 500, 750 and 1000 µg/kg (n=3). They noted shivering in mice injected the two highest doses of YTX, and just before death the mice had vigorous cramps and were jumping. No macroscopic changes are observed after lethal *i.p.* doses of YTX. Four out of five mice that died within 50-80 minutes from *i.p.* injections of YTX (2/3 at 750 µg/kg, and 3/3 at 1,000 µg/kg) showed vacuolation in the cardiac muscle, and intrecellular oedema, as examined by light microscopy (Aune *et al.*, 2002). No pathological changes were seen in lung, thymus, liver, pancreas, kidney, adrenal gland, jejunum, colon and spleen.

By electron microscopy, Terao *et al.* (1990) observed severe cardiac damage in mice receiving YTX at 500 μ g/kg *i.p.* Endothelial lining cells of the capillaries in the left ventricle were swollen and degenerated, and almost all cardiac muscle cells were swollen. The mitochondria became rounded and bundles of myofibrils and sarcoplasmic reticulum were separated. In a study of Aune *et al.* (2002), less severe ultrastructural changes in the heart of

mice given 1000 μ g/kg of YTX *i.p.* were observed up to one hour after treatment: swelling myocardial muscle cells in the wall of the left ventricle and separation of myofibrils and mitochondria, the latter organelles being rounded in appearance. These changes were more pronounced in the vicinity of capillaries.

The apparent discrepancy in the severity of the response of the heart to YTX between the study of Terao *et al.* (1990) and Aune *et al.* (2002) is unclear. Differences in toxin purity and mice strain could be explanations.

According to Terao *et al.* (1990), no ultrastructural changes were seen in liver, pancreas, lungs, adrenals, kidneys, spleen or thymus.

Unlike YTX, di-desulfoYTX caused swelling and yellow colouring of the liver within hours of administration of toxic doses (Terao *et al.*, 1990). The colouring of the livers was associated with increases in hepatic fat levels and severe fatty degeneration of the liver, with swollen mitochondria and increased phagocytic activity. Di-desulfoYTX had minimal effects on the heart, with only a slight deposition of fat in the cardiac muscle. It is interesting to note that desulfation of YTX resulted in fundamental changes in the target organ, but it is a question whether di-desulfoYTX should be included in the opinion at all since this compound has not been detected in algae or shellfish, but was produced via solvolysis of YTX. According to Ogino *et al.* (1997), the reason for studying di-desulfoYTX is the possible conversion of YTX to the desulfated analogue by intestinal microorganisms.

Since YTX provoked death showing symptoms from the nervous system (motor discoordination), Franchini and co-workers (2004a,b) studied the effect of a single dose of YTX (10 and 420 μ g/kg b.w. given *i.p.*) on the central nervous system in Swiss CD1 mice. While the cerbral cortex was not affected at any of the doses, the higher dose caused damage to the Purkinje cells of the cerebellar cortex. Changes in intracellular calcium binding proteins and modification of the cytoskeletal components were observed. Furthermore, histopathological examination of the thymus revealed that both doses caused structural changes and apoptosis particularly in the cortico-medullar junction resulting in a reduced population of mature thymocytes. Mitoses were noted particularly in the cortex. In the duodenum the highest dose caused infiltration of blood cells and lymphocytes particularly in the Payer's patches showed signs of apoptosis. Cytokine responses in both duodenum and thymus were found at both doses.

Contrary to the findings by Franchini *et al.* (2004b), neither Aune *et al.* (2002) exposing female NMRI mice up to 1000 μ g/kg b.w. *i.p.* of YTX nor Terao *et al.* (1990) exposing mice at 500 μ g/kg b.w. *i.p.* observed any structural or ultra structural (Terao *et al.*, 1990) changes in the thymus. These discrepancies may be due to different purities of the toxins and the use of different strains of mice.

Data on *i.p.* toxicity of YTX-group toxins were recently summarised by Munday *et al.* (2008), as shown in Table 10.



Table 10: Acute toxicity of YTX-group	toxins by intraperitoneal	injection	in mice.
---	---------------------------	-----------	----------

Compound	Mouse strain	Mouse sex	Parameter	ua/ka body weight	Reference
Yessotoxin	ddY	Male		Between 80 and 100	Ogino et al 1997
Yessotoxin	NMRI	Female		Between 500 and 750	
Yessotoxin	NMRI	Female		314	
Yessotoxin	NMRI	Male		412	
Yessotoxin	ICR (CD-1)	Female		380	
Yessotoxin	ICR (CD-1)	Male		462	
Yessotoxin	Swiss (CFW-1)	Female		269	
Vessotoxin	Swiss (CFW-1)	Male		328	
Vessotoxin	CD_1	Female		512 (312-618)*	Tubaro et al. 2003
Yessotoxin		Male		300**	Terao <i>et al.</i> 1990
Yessotoxin	Swiss albino	Female		112 (96-131)*	Munday et al. unnublished results
Vessotovin	C57 Black	Female		136 (112-166)*	Munday et al. unpublished results
1a-HomoVTX		Female		<i>444</i> (315-830)*	Tubaro et al. 2003
1a-HomoVTX	not reported	not reported	LD50	100	Satake et al. 1007
45 HudroxyVTY	not reported	not reported	Lethal dose	~ 500	Satake et al., 1997
45-Hydroxy-12-bomoVTX		Female	Lethal dose	No deaths at 750	Tubaro et al. 2003
55 CarboxyVTX	not reported	not reported	Lethal dose	~ 500	Ciminiello et al. 2000a
55 Carboxy 1a homoVTY	not reported	not reported	Lethal dose	~ 500	Ciminiello et al., 2000a
45 46 47 TriperVTV	not reported	not reported	Lethal dose	~ 300	Sataka at al. 1006
		Molo		~ 220	Jalake et al., 1990
	IUR not reported	IVIAIE	LD ₅₀	501	
1-Desuitor TX			Lethal dose	~ 500	Daiguji et al., 1998
I, 3-Enone isomer of neptanor-41-0x0Y IX	Swiss albino	Female		No deaths at 5,000	Wiles et al., 2004
homoVTV	Swiss aidino	remale	Lethal dose	No deaths at 5,000	whes et al., 2005

LD₅₀= lethal dose – the dose required to kill half the members of a tested animal population * Figures in brackets indicate 95% confidence limits. ** This figure is the LD₅₀ at 3 hours after dosing. Since deaths from YTX intoxication occur at times greater than 3 hours, the true LD₅₀ in this experiment is likely to lower than that indicated.



As can be seen from Table 10, the reported LD_{50} values for YTX vary considerably, from approximately 100 to between 500 and 750 µg/kg. These disparities could not be explained by use of different strains of mice only as comparisons between different strains in the same experiment only showed a variation of 1.4 fold between the least and most susceptible strain (Aune *et al.*, 2008). When comparing males and females of three different strains, female mice were more susceptible than males, see Table 10 (Aune *et al.*, 2008). In this experiment with three strains and both sexes, the average LD_{50} for females was 321 µg/kg, and for the males 400 µg/kg, and a total average for both sexes at 360 µg/kg. The stability of YTX and the storage conditions for the toxin used in different studies may play a more important role for the variability of the measured LD_{50} values (Aune *et al.*, 2008). Recent studies indicate that YTX is unstable during long-term storage (> 6 months) in the dry state (Loader *et al.*, 2007).

With the differences in reported LD_{50} of YTX, establishment of TEFs of the analogues is difficult. Also, toxicities for these have been given as "lethal dose" rather than LD_{50} in many instances. However, from Table 10, it appears that 1a-homoYTX and di-desulfoYTX are approximately as toxic as YTX, based on the given LD_{50} results reported. For analogues with information on lethal dose only, crude estimates indicate that the acute *i.p.* toxicity of 45,46,47-trinorYTX is close to that of YTX, while carboxy- and 45-hydroxyYTX appears to be slightly less toxic.

10.2.1.2 Toxicity following oral administration

In several studies no deaths were recorded in mice given YTX by gavage at 0.5 mg/kg b.w. (Terao *et al.*, 1990), 1 mg/kg b.w. (Ogino *et al.*, 1997), 2 mg/kg b.w. (Tubaro *et al.*, 2003), 10 mg/kg b.w. (Aune *et al.*, 2002). No clinical signs were observed in mice following a single oral dose of 50 mg YTX/kg b.w. (unpublished results, Munday *et al.*, 2008), however, no histopathology or clinical biochemistry was done.

In a study by Aune *et al.* (2002), two experiments were undertaken, using female NMRI mice (15-19 g). In the first experiment, *i.p.* toxicity of YTX in doses between 0.1 and 1.0 mg/kg (reported in detail above) was compared with oral toxicity of YTX 1.0, 2.5, 5.0, 7.5 or 10.0 mg/kg (n=3 per group) as a single dose by gavage. One mouse per dose was sacrificed after 5 hours, the others after 24 hours. No mice died from oral exposure, even at 10 mg/kg YTX. Ten different organs were studied by light microscopy. Slight oedema was only seen in the myocardium at the two highest oral doses (7.5 and 10 mg/kg) and in one of the control mice. The changes were similar in mice given 10 mg/kg b.w. *p.o* and 1 mg/kg b.w. *i.p.* In the second experiment, mice received YTX by gavage at 2.5, 5 or 10 mg/kg (n=2). Animals surviving the treatment were killed after 1 hour. Tissues were taken from the heart and six other organs and examined by light microscopy indicated no effects in any organs except the myocardium. By electron microscopy only slight changes in muscle cells close to the capillaries



were observed and most of the myocardium was unchanged at a dose of 2.5 mg/kg. At 5 mg/kg, moderate swelling of myocardial cells was seen near capillaries with protrusions into the capillary space. At the highest dose (10 mg/kg), swelling of myocardial cells and separation of organelles was observed, most pronounced close to the capillaries

Tubaro *et al.* (2003) studied the effects of YTX given by gavage to female CD-1 mice (18-20 g). Groups of five mice were given 1 and 2 mg/kg of YTX and observed for 24 hours. No signs of toxicity were observed in the mice, and no macroscopic changes were seen in major organs. By histopathological examination of the same organs using light microscopy, no morphological changes were seen at any of the doses. However, by using electron microscopy, analysis of the heart from mice given both doses showed presence of some alterations of myocardiocytes adjacent to capillaries. In particular, cytoplasmic protrusions of cardiac muscle cells into the capillary space were seen, along with rounding of mitochondria and packing and alterations of muscle fibres. However, the authors noted that no changes were observed in plasma lactate dehydrogenase (LDH) or creatinine phosphokinase (CK) indeces of cardiac tissue damage. According to Tubaro *et al.* (2003), no clinical signs of toxicity were observed in mice given 1 mg/kg of 1a-homoYTX or 45-hydroxyYTX, however, cytoplasmic protrusions of myocardiocytes, rounding of mitochondria and fibre modifications were reported.

In a follow up study (Tubaro et al., 2004), female CD-1 mice (18-20 g, n=5) were administered YTX by gavage at 2 mg/kg/day, or 1a-homoYTX or 45-hydroxy-1a-homoYTX at 1 mg/kg/day for seven days. Twenty-four hours after the last treatment, the mice were killed and submitted to necroscopic examinations. Liver, heart, lungs, kidney, spleen, stomach, duodenum, jejunum, colon, rectum, pancreas, thymus, uterus, ovaries, skeletal muscle, brain and spinal cord were sampled for histolopathological analysis by light microscopy. The heart tissue was also studied by electron microscopy. No significant differences in growth rate between treated mice and controls were observed. The necroscopic analysis and light microscopy examinations did not show any treatment-associated changes in the main organs. Electron microscopy of the heart revealed some changes in the myocardial muscle cells near capillaries, such as package of swollen mitochondria and alterations of cell boundary in mice treated with 2 mg/kg/day YTX. Similar modifications were observed in mice treated with 1a-homoYTX and 45-hydroxy-1ahomoYTX at 1 mg/kg/day. No apoptotic deoxyribonucleic acid (DNA) fragmentation was observed as a result of repeated oral exposure to YTX and the two analogues. The plasma levels of LDH and CK which are indicators of myocardial necrosis were not elevated. Neither was any apoptotic DNA fragmentation of heart muscle cells observed. According to the authors, it was noteworthy that the changes were limited to cells near the capillaries and that other parts of the myocardium were not affected. The effects observed were not more pronounced than those observed following a single administration at the same dose level.

In another study (Espenes *et al.*, 2006), NMRI female mice (14 g b.w. at start) were exposed by gavage for YTX 7-times during 21 days, each dose was 1, 2.5 or 5 mg/kg (n=3). Five controls received vehicle at the same days. The mice were killed three days after the last treatment. The



heart, lung, liver, kidney, small intestine, spleen, thymus, pancreas, brain, testes and adrenals were examined by light microscopy. In addition, the myocardium was also studied by electron microscopy. No clinical symptoms were observed in any of the groups exposed to YTX. There were no differences in body weight gain between YTX-exposed mice and controls. By light microscopy, no pathological effects were observed. However, by electron microscopy, some vacuoles of uncertain significance were seen in the myocardium in mice at the highest dose of YTX (5 mg/kg, seven times). Compared with previous studies by the same authors (Aune *et al.*, 2002), fewer morphological changes were seen in this study. The authors speculated whether this may be due to repair mechanisms as the changes in that study were observed up to one hour after exposure, whereas the time between treatment and examination was 3 days.

In a recent study by Tubaro *et al.* (2008a), groups of three mice (female CD-1, 18-20 g), were treated daily for seven days with YTX (1 mg/kg/day) or vehicle by gavage. Clinical signs, food consumption and body weight were recorded at 24 hours, 30 days and 90 days after the last treatment. At each time, three mice in each group were killed and blood samples and samples from the main organs were taken for histological analyses. In particular, no histopathological changes were observed in the thymus. Heart, liver, kidneys and cerebellum were also sampled for transmission electron microscopy. No mortality or other treatment-related changes, including histological or hematoclinical parameters were observed in the YTX treated mice. No ultrastructural alterations were seen in the liver, kidneys or cerebellum. However, changes in cardiac muscle cells near the capillaries (clusters of rounded mitochondria and disorganization of myofibrils) were observed 24 hours after the last treatment. These changes were also noted 30 days after treatment, but less evident compared with those seen at 24 hours. No difference in cardiac muscle cells between controls and YTX-treated mice were seen after 90 days. This indicates recovery of the ultrastructural alterations.

Tubaro and co-workers (2008b) also studied possible ultrastructural effects of YTX on skeletal muscle following oral exposure of female CD 1 mice to 1 and 2 mg/kg b.w. of YTX daily for seven days. No changes, including similar changes to those previously seen on cardiac muscle cells, were seen following YTX exposure.

Repeated oral administration of YTX to mice (1 mg/kg/day, for 7 days) was found to stabilize Ecadherin (Callegari *et al.*, 2006), an effect that could be the result of the inhibition of endocytosis and degradation of E-cadherin by YTX (Callegari and Rossini, 2008). On the basis of these findings, it can be concluded that YTX alters the disposal of E-cadherin both *in vitro* and *in vivo*.

10.3 Relative potency of YTX-group toxins

There is no information available on LD_{50} of YTX-group toxins via the oral route. The majority of oral toxicity studies are done with YTX, and a few with 1a-homoYTX and 45-hydroxyYTX. In neither case have the analogues resulted in lethal effects, due to low oral toxicity. Like for



other marine biotoxins, there is more information on acute *i.p.* toxicity of YTX and several analogues. With the differences in reported LD₅₀ of YTX following *i.p.* administration, establishment of TEFs of the analogues is difficult. Also, toxicities for these have been given as "lethal dose" rather than LD₅₀ in many instances. It appears that 1a-homoYTX and didesulfoYTX are approximately as toxic as YTX (Table 10). For analogues with information on lethal dose only, crude estimates indicate that the acute *i.p.* toxicity of 45,46,47-trinorYTX is close to that of YTX, while carboxy- and 45-hydroxyYTX appears to be slightly less toxic. Hence, with the exception of 45-hydroxy-1a-homoYTX it is concluded that the data available are insufficient to distinguish between YTX and its analogues with respect to *i.p.* lethality LD₅₀ values and hence also to establish TEFs/relative potencies for YTX-group toxins. For 45-hydroxy-1a-homoYTX, which showed no lethality up to 750 µg/kg b.w. *i.p.*, a TEF of 0.5 is assigned. The most commonly occurring analogues have therefore been assigned the following TEFs:

YTX	1
1a-homoYTX	1
45-hydroxyYTX	1
45-hydroxy-1a-homoYTX	0.5

Relative potencies have also been studied in *in vitro* systems and the results indicate that the proposed TEFs do not underestimate the toxicity of the tested analogues (Ferrari *et al.*, 2004; Pazos *et al.*, 2005).

10.4 Chronic toxicity and carcinogenicity

No long term in vivo studies on YTX has been identified.

10.5 Genotoxicity

No data are available.

11. Observations in humans

There are no reports of human illness associated with YTXs.

12. Hazard characterisation

There are no long term *in vivo* toxicity studies of YTX and hence no data are available for the establishment of a tolerably daily intake (TDI). There is no data related to toxicity in humans. In



view of the potential for acute toxicity of YTX-group toxins, the CONTAM Panel decided to establish an acute reference dose (ARfD) on the basis of acute oral toxicity in mice.

YTX toxicity following oral administration was examined in a series of studies (Aune *et al.*, 2002; Tubaro *et al.*, 2003, 2004, 2008a; Espenes *et al.*, 2006). In these studies YTX was administered by gavage in single doses up to 10 mg/kg b.w. or repeated doses up to 5 mg/kg b.w. given 7 times. Since no lethality and no clinical symptoms were observed at doses that were far above those being lethal by *i.p.* administration, it is evident that YTX is far less toxic when given by the oral route.

Following *i.p.* or *p.o.* administration, the heart has been identified as a primary target organ. By the use of light microscopy slight oedema in the myocardium was observed down to a single oral dose of 7.5 mg/kg b.w. with a no-observed-effect level (NOEL) of 5 mg/kg b.w. (Aune *et al.*, 2002). In the same study by the use of electron microscopy moderate changes in myocardial muscle cells close to capillaries were already seen at 5 mg/kg b.w. with only marginal changes at 2.5 mg/kg b.w. In another study by the same group (Espenes *et al.*, 2006) YTX were given in 7 repeated oral doses (1, 2.5 and 5 mg/kg b.w.) during 21 days followed by autopsy three days after the last dosing. Except for some vacuoles of uncertain significance at the highest dose, no significant changes in the heart, even in areas around capillaries were observed by electron microscopy.

In a series of studies by Tubaro *et al.* (2003, 2004, 2008a), ultrastructural changes in the myocardial muscle cells close to capillaries were observed down to single oral doses of 1 mg/kg b.w. of YTX or 1a-homoYTX and 45-hydroxyYTX. Similar changes were also observed after 7 repeated doses of 1 and 2 mg/kg b.w., respectively, in two independent studies (Tubaro *et al.* 2004, 2008a). In the latter study the mice were followed for 30 and 90 days after the last dosing and the changes were less pronounced after 30 days and were absent after 90 days, indicating that these changes were reversible. It should be noted that at doses of 2 mg/kg b.w. of YTX and below no changes were observed by light microscopy and there were no changes in plasma levels of LDH or CK, indicators of heart muscle damage. Neither was apoptosis observed in the heart muscle cells.

The small and reversible ultra-structural changes in the heart muscle appear to be treatment related, but at the lowest oral doses (1-2 mg/kg b.w.) they are only inconsistently observed by different authors. These studies have shortcomings i.e. in the reporting, and there is no information on whether the histopathological examination by light microscopy and in particular by electron microscopy was carried out in a blinded way with respect to treatment. Neither was it systematically described how the samples from the heart of each mice were examined in order to establish significant differences between the various treatment groups, (e.g. quantitative measurements of mitochondria in sections from treated and control animals). The clinical and toxicological significance of these findings are uncertain. However, cardiotoxicity of YTX at low



doses is supported by *in vitro* studies on heart muscle cells where short incubations with YTX inhibited beating activity $(10^{-7}-10^{-6} \text{ M})$ and cell viability (10^{-8} M) (Dell'Ovo *et al.*, 2008).

The Panel noted that the ultrastructural changes induced by YTX apparently are reversible and were not accompanied by any leakage of enzymes to serum, indicative of cardio-myocyte necrosis, or any apoptotic activity. Furthermore, no such myocardial changes were observed in mice orally exposed 7 times with intervals of 3 days at doses up to 5 mg/kg b.w. of YTX when electron microscopy examination was done 3 days after the last dose.

In its derivation of an ARfD the CONTAM Panel decided to use the dose of 5 mg/kg b.w. as the most robust NOAEL for acute cardiotoxicity caused by YTXs as identified by light microscopy. Considering the ultrastructural changes in the myocardium that have inconsistently been reported below this dose level, the CONTAM Panel noted that these changes may be reversible, and that they were not accompanied by leakage of enzymes to serum. There were no indications of myocardial damage as identified by light microscopy. However, because it is uncertain whether the ultrastructural changes should be considered as adverse or not, the CONTAM Panel decided to apply a factor of 2 in addition to the default uncertainty factor of 100 to establish an ARfD of $25 \mu g$ YTX equivalents/kg b.w.

13. Risk characterisation

Because YTX-group toxins have potential for acute toxic effects, the Panel concluded that the identification of a high portion size rather than a long term average consumption is of importance to assess the health risk of the consumers. It considered the 95th percentile as a realistic estimate of the portion size for high consumers, and chose the figure of 400 g to be used in acute exposure assessments.

As was shown in Table 7 consumption of a 400 g portion of shellfish meat containing YTXgroup toxins at the current EU limit of 1 mg YTX eq./kg shellfish meat would result in an intake of 400 μ g toxin (equivalent to 6.7 μ g/kg b.w. in a 60 kg adult). This intake is below the ARfD of 25 μ g YTX eq./kg b.w. (equivalent to 1500 μ g YTX eq. per portion for a 60 kg adult) and consequently does not pose any health risk.

As explained in chapter 6 the Panel assumed that all shellfish samples showing a negative response in MBAs will reach the market and will thus be consumed. Therefore, the concentration data derived by LC-MS/MS for these samples (Table 6) could be used to estimate the dietary intake of YTX-group toxins.

Based on the Norwegian occurrence data consumption of a 400 g portion of shellfish meat containing YTX-group toxins at 315 μ g YTX eq./kg shellfish meat corresponding to the 95th percentile of the concentration (see Table 6) would result in an intake of 125 μ g YTX-group toxins (equivalent to 2.1 μ g/kg b.w. in a 60 kg adult). This intake is well below the ARfD of 25

 μ g YTX eq./kg b.w. The same is true for the specific situation in Italy (North Adriatic sea) where consumption of a 400 g portion of shellfish containing the 95th percentile of the concentration YTX-group toxins (799 μ g YTX eq./kg shellfish meat) leads to intake of 5.3 μ g/kg b.w. This indicates that there is no acute health risk with respect to consumption of shellfish containing the current levels of YTX-group toxins found on the market.

The LC-MS/MS data (Table 6) show that none of the samples from the Norwegian and Italian data set that tested negative in the MBA, exceeded a value of 3.75 mg YTX eq./kg shellfish meat. Therefore the CONTAM Panel concluded that a 60 kg person, consuming a portion of 400 g of shellfish currently present on the market, would not exceed the ARfD of 25 μ g/kg b.w.

The CONTAM Panel noted that, even taking into consideration all reported YTX occurrence data (MBA negative and MBA positive results) and thereby disregarding the current EU regulatory system, consumers of shellfish in Norway would not exceed the ARfD when consuming a 400 g portion. In Italy (North Adriatic Sea), the ARfD would be exceeded under these circumstances by 2.9% of the consumers.

The CONTAM Panel concluded that in order for a 60 kg adult to avoid exceeding a dose of 1500 μ g YTX equivalents, corresponding to the ARfD of 25 μ g YTX equivalents/kg b.w., a 400 g portion should not contain more than 3.75 mg YTX eq./kg shellfish meat. This level is above the current EU limit value of YTXs of 1 mg/kg shellfish flesh.

14. Uncertainty

The evaluation of the inherent uncertainties in the assessment of exposure to YTX-group toxins has been performed following the guidance of the Opinion of the Scientific Committee related to Uncertainties in Dietary Exposure Assessment (EFSA, 2006). In addition, the draft report on "Characterizing and Communicating Uncertainty in Exposure Assessment" which is in preparation to be published as WHO/IPCS monograph, has been considered (WHO/IPCS, 2007). According to the guidance provided by the EFSA opinion (2006) the following sources of uncertainties have been considered: Assessment objectives, exposure scenario, exposure model, and model input (parameters).

14.1 Assessment objectives

The objectives of the assessment were clearly specified in the terms of reference and the Panel prepared a risk assessment including the derivation of an ARfD, description of the different analytical methods, and an exposure assessment for the current situation. The uncertainty of the assessment objectives is considered to be negligible.



14.2 Exposure scenario

The estimate of exposure is based on measurements from only two European Countries (Norway and Italy (North Adriatic Sea)). The exposure scenario may therefore lead to overestimation of exposure when extrapolating these data to the whole European population.

Uncertainty possibly introduced by non-consideration of cooking for quantitative exposure assessment is considered to be negligible as an impact for final conclusions, because these toxins are heat stable. As the majority of the occurrence data are derived from raw shellfish and cooking leads to increased concentrations, the exposure might be somewhat underestimated.

14.3 Exposure model

The high numbers of samples having levels below LOD may introduce uncertainties to the overall estimate. However, the uncertainties regarding values below the LOD are considered to be negligible, as they do not have a major influence on the risk characterisation.

Uncertainty also arises from the fact that exposure estimates were based on occurrence data from pre-market control samples. These samples may not reflect the "real" range of occurrence of YTXs in the shellfish on the market, but may result in an overestimation of the exposure.

14.4 Model input (parameters)

Parameter uncertainty is due to using occurrence results "only" from two member states, one of which is considered to be a worst case. Although analytical methodology is assumed to deliver comparable results, appropriate calibration standards for YTX were not always available. The data were produced with non-certified calibration standards which may not be appropriate for quantification. Uncertainties regarding the analytical methodology of YTX have been considered in the opinion by taking into account the data from Norway and Italy, having major differences in LOD and LOQ.

TEFs have been used to convert the concentrations of the YTX-group toxins into YTX equivalents. As pointed out in chapter 10.3, these TEFs are based on limited *i.p.* toxicity data. However, due to the low exposure the model input parameters do not lead to major changes in the overall results.



14.5 Summary of uncertainties

In Table 11 a summary of the uncertainty evaluation is presented, highlighting the main sources of uncertainty and indicating an estimate of whether the respective source of uncertainty might have led to an over- or underestimation of the exposure or the resulting risk.

Table 11: Summary of qualitative evaluation of the impact of uncertainties on the risk assessment of the dietary exposure of YTX-group toxins.

Sources of uncertainty	Direction and magnitude
Uncertainty in analytical results	+/- ^{a)}
Extrapolation of occurrence data from two European Countries to whole Europe	+
Incomplete database for shellfish consumption in Europe; data only from limited number of Member States and limited data on shellfish species other than mussels	+
Influence of samples below the LOD on deterministic and probabilistic exposure estimate	+/-
Consideration of shellfish sampled for pre-market control for systematic dietary estimation of exposure	+
Influence of cooking and processing	-
Use of TEFs for estimating YTX equivalents	+
Limitation in the database for establishing the ARfD	+

a)+, ++, +++ = uncertainty with potential to cause small, medium or large over-estimation of exposure/risk -, --, --- = uncertainty with potential to cause small, medium or large under-estimation of exposure/risk (EFSA, 2006).

The CONTAM Panel considered the impact of the uncertainties on the risk assessment of exposure to YTX-group toxins from shellfish consumption and concluded that due to the low risk involved in YTX exposure, there is minimum impact of uncertainties on the outcome of the risk assessment.

CONCLUSIONS

Hazard identification and characterisation

• Yessotoxin group toxins (YTXs) are primarily produced by the marine dinoflagellate *Protoceratium reticulatum*. They are polyether compounds, consisting of 11 contiguously transfused ether rings, an unsaturated side chain, and two sulphate esters. More than 90 YTXs are known, but only a few dozens have been fully identified. The most important YTX-group toxins are YTX, 1a-homoYTX, 45-hydroxyYTX, and 45-hydroxy-1a-homoYTX.



- The primary target organ for YTX toxicity in mice appears to be the heart, both after intraperitoneal (*i.p.*) and oral acute exposure of mice. Lethality has been shown following *i.p.*, but not after oral exposure.
- The data on *i.p.* lethality of YTX and its analogues 45-hydroxyYTX and 1a-homoYTX did not allow any distinction between their toxic potencies, and therefore they should have equal weight when summing up total YTX equivalents (YTX eq.). The toxicity of 45-hydroxy-1a-homoYTX is less, and an interim toxic equivalence factor (TEF) factor of 0.5 was used by the Panel on Contaminants in the Food Chain (CONTAM Panel).
- There are no reports on adverse effects in humans associated with YTXs.
- There are no studies on chronic effects of YTX in animals and therefore no tolerable daily intake (TDI) can be established.
- Although the oral toxicity is not well defined, the CONTAM Panel considered it appropriate to set an acute reference dose (ARfD) on the basis of cardiotoxicity in order to facilitate the risk assessment of acute exposure to YTXs.
- In its derivation of an ARfD the CONTAM Panel decided to use the dose of 5 mg/kg b.w. *p.o.* as the most robust no-observed-adverse-effect level (NOAEL) for acute cardiotoxicity caused by YTXs as identified by light microscopy. The CONTAM Panel noted that ultrastructural changes in the myocardium have inconsistently been reported below this dose level. It also noted that these changes may be reversible, and that they were not accompanied by leakage of enzymes to serum. There were no indications of myocardial damage as identified by light microscopy. However, because it is uncertain whether the ultrastructural changes should be considered as adverse or not, the CONTAM Panel decided to apply a factor of 2 in addition to the default uncertainty factor of 100 to establish an ARfD of 25 µg YTX equivalents/kg b.w.

Occurrence/Exposure

- Occurrence data on YTXs were only available from a limited number of countries.
- Levels determined by liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) in samples that tested negative in the mouse bioassay (MBA) have been used for exposure assessment.
- Consumption data for shellfish are only available for a few Member States. These data do not always distinguish between shellfish species nor the type of processing. In addition, different study designs were used in the collection of the consumption data.
- From the available data, the CONTAM Panel identified the figure of 400 g as high portion size to be used in acute exposure assessments



Risk characterisation

- Consumption of a 400 g portion of shellfish meat containing YTXs at the current European Union (EU) limit of 1 mg YTX eq./kg shellfish meat would result in an intake of 400 µg toxin (equivalent to 6.7 µg/kg b.w. in a 60 kg adult). This intake is below the ARfD of 25 µg YTX eq./kg b.w (equivalent to 1500 µg YTX eq. per portion for a 60 kg adult) and consequently does not pose any health risk.
- Consumption of a 400 g portion of shellfish meat containing YTXs at 315 or 799 μ g YTX eq./kg shellfish meat (corresponding to the 95th percentile of the concentration in the Norwegian and Italian data set that tested negative in the MBA, respectively) would result in an intake of 126 or 320 μ g YTXs (corresponding to 2.1 or 5.3 μ g YTX eq./kg b.w. for a 60 kg adult, respectively). For both countries this intake is below the ARfD of 25 μ g YTX eq./kg b.w., indicating that there is no health risk.
- The LC-MS/MS results show that none of the samples from the Norwegian and Italian data set that tested negative in the MBA, exceeded a value of 3.75 mg YTX eq./kg shellfish meat. Therefore the CONTAM Panel concluded that a 60 kg person, consuming a portion of 400 g of shellfish currently present on the market, would not exceed the ARfD of 25 µg/kg b.w.
- Taking into consideration all reported YTX occurrence data, thus both the MBA negative and MBA positive results, and thereby disregarding the current EU regulatory system, consumers of shellfish in Norway would not exceed the ARfD when consuming a 400 g portion. In Italy (North Adriatic Sea), the ARfD would be exceeded under these circumstances by 2.9% of the consumers.
- The CONTAM Panel concluded that in order for a 60 kg adult to avoid exceeding a dose of 1500 µg YTX equivalents, corresponding to the ARfD of 25 µg YTX equivalents/kg b.w., a 400 g portion of shellfish should not contain more than 3.75 mg YTX eq./kg shellfish meat. This level is above the current EU limit value of YTXs of 1 mg/kg shellfish flesh.

Methods of analysis

- The MBA is the officially prescribed reference method in the EU for the determination of YTXs. The method has shortcomings, e.g. it is not specific, not quantitative and has a high uncertainty at the level of the current regulatory limit.
- LC-MS/MS methods have the greatest potential to replace the MBA. The LC-MS/MS methods also have the possibility for multi-toxin group detection/quantification.
- Neither the MBA, nor the (bio)chemical alternative methods have been formally validated in interlaboratory studies, following recognized protocols.



RECOMMENDATIONS (INCL. KNOWLEDGE/DATA GAPS)

Hazard identification and characterisation

- There is a need for clarification of the molecular mechanism of action of YTX and its analogues and the toxicological significance of the ultrastructural changes seen in the heart.
- Further information on the oral toxicity and relative potency of individual YTX-group toxins is needed.
- Information is needed on the oral toxicity of YTXs when combined with other lipophilic toxins that often co-occur in contaminated shellfish, such as okadaic acid (OA), azaspiracids (AZAs) and pectenotoxins (PTXs).

Occurrence/Exposure

• There is a need for more detailed data on shellfish consumption including data on portion size, frequency, individual shellfish species and processing of shellfish

Methods of analysis

- Certified standards for relevant individual YTXs and certified tissue reference materials with relevant compositions and levels of YTXs are required.
- It should be investigated if reference methods can be based on performance criteria, thereby allowing the use of several methods rather than a single specific method. The feasibility of the single laboratory validation concepts should be further explored, but validation by interlaboratory trials should be the long-term objective.

REFERENCES

- Aasen JAB, Samdal IA, Miles CO, Dahl E, Briggs LR and Aune T, 2005. Yessotoxins in Norwegian blue mussels (*Mytilus edulis*): uptake from *Protoceratium reticulatum*, metabolism and depuration. Toxicon 45, 265-272.
- Aasen JAB, Espenes A, Rehmann N, Hess P, Miles CO and Aune T, 2008. Combined oral toxicity of azaspiracid-1 and yessotoxin in female NMRI mice. Manuscript *in prep*.
- Adolf T, Schneider R, Eberhardt W, Hartmann S, Herwig A, Heseker H, Hünchen K, Kübler W, Matiaske B, Moch KJ and Rosenbauer J: Band III Ergebnisse der Nationalen Verzehrsstudie (1985-1988) über die Lebensmittel- und Nährstoffaufnahme in der Bundesrepublik Deutschland, VERASchriftenreihe, 1995. S 145 Abb 6.56.
- Alfonso A and Alfonso C, 2008. Pharmacology and mechanism of action of Yessotoxin: Biological detection. In: Seafood and Freshwater toxins: Pharmacology, Physiology and Detection (Botana, L.M., ed.). 2nd edition, CRC Press (Taylor and Francys Group), Boca Raton, USA, pp. 315-328.
- Alfonso A, De la Rosa L, Vieytes MR, Yasumoto T and Botana LM, 2003. Yessotoxin, a novel phycotoxin, activates phosphodiesterase activity Effect of yessotoxin on cAMP levels in human lymphocytes. Biochem. Pharmacol. 65, 193-208.
- Alfonso A, Vieytes MR, Yasumoto T and Botana LM, 2004. A rapid microplate fluorescence method to detect yessotoxins based on their capacity to activate phosphodiesterases. Anal. Biochem. 326, 93-99.
- Alfonso C, Alfonso A, Vieytes MR, Yasumoto T and Botana LM, 2005. Quantification of yessotoxin using the fluorescence polarization technique and study of the adequate extraction procedure. Anal. Biochem. 344, 266-274.
- Alfonso C, Alfonso A, Pazos MJ, Vieytes MR, Yasumoto T, Milandri A, Poletti R and Botana L. M, 2007. Extraction and cleaning methods to detect yessotoxins in contaminated mussels. Anal. Biochem. 363, 228-238.
- Aune T, Sørby R, Yasumoto T, Ramstad H and Landsverk T, 2002. Comparison of oral and intraperitoneal toxicity of yessotoxin towards mice. Toxicon 40, 77-82.
- Aune T, Larsen S, Aasen JAB, Rehmann N, Satake M and Hess P, 2007. Relative toxicity of dinophysistoxin-2 (DTX-2) compared with okadaic acid, based on acute intraperitoneal toxicity in mice. Toxicon 49, 1-7.
- Aune T, Aasen JAB, Miles CO and Larsen S, 2008. Effect of mouse strain and gender on LD₅₀ of yessotoxin. Toxicon 53, 535-540.



- Bianchi C, Fato R, Angelin A, Trombetti F, Ventrella V, Borgatti AR, Fattorusso E, Ciminiello P, Bernardi P, Lenaz G and Parenti Castelli G, 2004. Yessotoxin, a shellfish biotoxin, is a potent inducer of the permeability transition in isolated mitochondria and intact cells. Biochim. Biophys. Acta 1656, 139-147.
- Briggs LR, Miles CO, Fitzgerald JM, Ross KM, Garthwaite I and Towers NR, 2004. Enzymelinked immunosorbent assay for the detection of yessotoxin and its analogues. J. Agric. Food Chem. 52, 5836-5842.
- Callegari F and Rossini GP, 2008. Yessotoxin inhibits the complete degradation of E-cadherin. Toxicology 244, 133-144.
- Callegari F, Sosa S, Ferrari S, Soranzo MR, Pierotti S, Yasumoto T, Tubaro A and Rossini GP, 2006. Oral administration of yessotoxin stabilizes E-cadherin in mouse colon. Toxicology 227, 145-155.
- Ciminiello P, Fattorusso E, Forino M, Magno S, Poletti R and Viviani R, 1999. Isolation of 45hydrosyyessotoxin from mussels of the Adriatic Sea. Toxicon 37, 689-693.
- Ciminiello P, Fattorusso E, Forino M, Poletti R and Viviani R, 2000a. A new analogue of yessotoxin, carboxyyessotoxin, isolated from Adriatic Sea mussels. Eur. J. Org. Chem. 2000, 291-295.
- Ciminiello P, Fattorusso E, Forino M, Poletti R and Viviani R, 2000b. Structure determination of carboxyhomoyessotoxin, a new yessotoxin analogue isolated from Adriatic mussels. Chem. Res. Toxicol. 13, 770-774.
- Daiguji M, Satake M, Ramstad H, Aune T, Naoki H and Yasumoto T, 1998. Structure and fluorometric HPLC determination of 1-desulfoyessotoxin, a new yessotoxin analog isolated from mussels from Norway. Nat. Toxins 6: 235-239.
- De la Rosa L, Alfonso A, Vilariño N, Vieytes MR and Botana LM, 2001. Modulation of cytosolic calcium levels of human lymphocytes by yessotoxin, a novel marine phycotoxin. Biochem. Pharmacol. 61, 827-833.
- Dell'Ovo V, Bandi E, Coslovich T, Florio C, Sciancalepore M, Decorti G, Sosa S, Lorenzon O, Yasumoto T and Tubaro T, 2008. In vitro effects of yessotoxin on a primary culture of rat cardiomyocytes. Toxicol Sci. *In press*.
- Draisci R, Ferretti E, Palleschi L, Marchiafava C, Poletti R, Milandri A, Ceredi A and Pompei M, 1999. High levels of yessotoxin in mussels and presence of yessotoxin and homoyessotoxin in dinoflagellates of the Adratic Sea. Toxicon 37, 1187-1193.



- EFSA (European Food Safety Authority), 2006. Opinion of the Scientific Committee related to Uncertainties in Dietary Exposure Assessment. http://www.efsa.europa.eu/EFSA/Scientific_Opinion/sc_op_uncertainty%20exp_en,5.pdf
- Espenes A, Aasen J, Hetland D, Satake M, Smith A, Eraker N and Aune T, 2006. Toxicity of YTX in mice after repeated oral exposure. In: Molluscan Shellfish Safety (Henshilwood K, Deegan B, McMahon T, Cusack C, Keaveney S, Silke J, O'Cinneide M, Lyons D and Hess P, ed.). Proceedings of the 5th International Conference on Molluscan Shellfish Safety, Galway, Ireland, June 14th-18th, 2004, pp. 419-423.
- FAO (Food and Agriculture Organization of the United Nations), 2004. Marine Biotoxins. FAO Food and Nutrition Paper 80. Food and Agriculture Organization, Rome, Italy. http://www.fao.org/docrep/007/y5486e/y5486e00.htm
- FAO/IOC/WHO (Food and Agriculture Organization of the United Nations/Intergovernmental Oceanographic Commission of UNESCO/World Health Organization), 2004a. Report of the Joint FAO/IOC/WHO ad hoc Expert Consultation on Biotoxins in Bivalve Molluscs, Oslo, Norway, September 26-30, 2004. http://www.fao.org/ag/agn/food/risk_biotoxin_en.stm
- FAO/IOC/WHO (Food and Agriculture Organization of the United Nations/Intergovernmental Oceanographic Commission of UNESCO/World Health Organization), 2004b. In Background document of the Joint FAO/IOC/WHO ad hoc Expert Consultation on Biotoxins in Bivalve Molluscs, Oslo, Norway, September 26-30, Yessotoxins (Speijers GJA, Rossini GP, Aune T, Holland P, McNabb P and Miles CO).
- Fernández ML, Míguez A, Cacho E, Martínez A, Diógene J and Yasumoto T, 2002. Bioensayos con mamíferos y ensayos bioquímicos y celulares para la detección de ficotoxinas, In Floraciones algales nocivas en el cono sur americano. (Sar EA, Ferrario ME and Reguera B, Eds.). pp 77-120, Instituto Español de Oceanografía, Pontevedra, Spain.
- Ferrari S, Ciminiello P, Dell'Aversano C, Forino M, Malaguti C, Tubaro A, Poletti R, Yasumoto T, Fattorusso E and Rossini GP, 2004. Structure-activity relationships of yessotoxins in cultured cells. Chem. Res. Toxicol. 17, 1251-1257.
- Fonfría ES, Vilariño N, Vieytes MR, Yasumoto T and Botana LM, 2008. Feasability of using a surface plasmom resonance-based biosensor to detect and quantify yessotoxin. Anal. Chim. Acta 67, 167-170.
- Franchini A, Marchesini E, Poletti R and Ottaviani E, 2004a. Lethal and sub-lethal yessotoxin dose-induced morpho-functional alterations in intraperitoneal injected Swiss CD1 mice. Toxicon. 44(1), 83-90.
- Franchini A, Marchesini E, Poletti R and Ottaviani E, 2004b. Acute toxic effect of the algal yessotoxin on Purkinje cells from the cerebellum of Swiss CD1 mice. Toxicon. 43, 347-352.



- Henderson L, Gregory J and Swan G, 2002. NDNS (National Diet and Nutrition Survey), National Diet and Nutrition Survey: Adults Aged 19 to 64 Years: volume 1: types and quantities of foods consumed, London: TSO.
- Hess P, Grune B, Anderson DB, Aune T, Botana LM, Caricato P, Van Egmond HP, Halder M, Hall S, Lawrence JF, Moffat C, Poletti R, Richmond J, Rossini GP, Seamer C and Vilageliu JS, 2006. Review: Three Rs approaches in marine biotoxin testing—the report and recommendations of a joint ECVAM/DG SANCO workshop (ECVAM workshop 55). ATLA-Altern. Lab. Anim. 34, 193-224.
- Hess P and Aasen JAB, 2007. Chemistry, origins and distribution of Yessotoxin and its analogues. In Chemistry and Biochemistry of Marine Biotoxins (Botana L. ed). Blackwell Publishing Ltd. Oxford, UK.
- Horwitz W, 1995. Protocol for the design, conduct and interpretation of method performance studies. Pure Appl. Chem. 67, 331-343.
- JMPR (Joint FAO/WHO Meetings on Pesticide Residues), 2002 Further guidance on derivation of the ARfD. Pesticide residues in food–2002. Report of the JMPR 2002, FAO Plant Production and Protection Paper, 172, FAO, Rome, pp. 4-8.
- Kistemaker C, Bouman M and Hulshof KFM, 1998. DNFCS (Dutch National Food Consumption Survey), Consumption of separate products by Dutch population groups - Dutch National Food Consumption Survey 1997-1998 (in Dutch), TNO-Nutrition and Food Research Institute, TNO-report V98.812, Zeist, The Netherlands.
- Leblanc J-C, Volatier J-L, Sirot V, Bemrah-Aouachria N, 2006. CALIPSO, Fish and seafood consumption study and biomarker of exposure to trace elements, pllutants and omega 3. The General Directorate for Foods of France's Ministry of Agriculture and Fisheries, AFSSA, the French Institute for Agronomy Research and the French Food Safety Agency INRA. http://www.afssa.fr/Documents/PASER-Ra-CalipsoEN.pdf
- Lee JS, Yanagi T, Kenna R and Uasumoto T, 1987. Fluorimetric determination of diarrhetic shellfish toxins by high-performance liquid chromatography. Agric. Biol. Chem. 51, 877-881.
- Leira F, Álvarez C, Vieites JM, Vieytes MR and Botana LM, 2002. Characterization of distinct apoptotic changes induced by okadaic acid and yessotoxin in the BE(2)-M17 neuroblastoma cell line. Toxicol. in Vitro 16, 23-31.
- Loader JI, Hawkes AD, Beuzenberg V, Jensen DJ, Cooney JM, Wilkins AL, Fitzgerald JM, Briggs LM and Miles CO, 2007. Convenient large scale purification of yessotoxin from *Protoceratium reticulatum* culture and isolation of a novel furanoyessotoxin. J. Agric. Food Chem. 55, 11093-11100.



- MacKenzie AL, Holland PT, McNabb P, Beuzenberg V, Selwood A and Suzuki T, 2002. Complex toxin profiles in phytoplankton and Greenshell mussels (Perna canaliculus), revealed by LC-MS/MS analysis. Toxicon 40, 1321-1330.
- McNabb P, Selwood AL and Holland PT, 2005. Multiresidue Method for Determination of Algal Toxins in Shellfish: Single-Laboratory and Inter-laboratory Study. J. AOAC Int. 88, 761-772.
- Malagoli D and Ottaviani E, 2004. Yessotoxin affects fMLP-induced cell shape changes in *Mytilus galloprovincialis* immunocytes. Cell Biol. Int. 28, 57-61.
- Malagoli D, Casarini L and Ottaviani E, 2006a. Algal toxin yessotoxin signalling pathways involve immunocyte mussel calcium channels. Cell Biol. Int. 30, 721-726.
- Malagoli D, Marchesini E and Ottaviani E, 2006b. Lysosomal as target of yessotoxin in invertebrate and vertebrate cells. Toxicol. Lett. 167, 75-83.
- Malaguti C and Rossini GP, 2001. Yessotoxin induces caspase activation and death of HeLa cells. Proceedings of the 2nd International Joint Meeting "In Vitro Models and Toxicity Mechanisms", Verona (Italy), May 30-Jun. 1, 2001; 35.
- Malaguti C, Ciminiello P, Fattorusso E and Rossini GP, 2002. Caspase activation and death induced by yessotoxin in HeLa cells. Toxicol. in Vitro 16, 357-363.
- Marcaillou-Le Baut C, Bardin B, Bardouil M, Bohec M, Maselin P and Truquet P, 1990. Étude de la décontamination de moules toxiques. Rapport IFREMER DERO-90-02 MR, p. 21.
- Miles CO, Wilkins AL, Hawkes AD, Selwood A, Jensen DJ, Aasen J, Munday R, Samdal IA, Briggs LR, Beuzenberg V and Mackenzie AL, 2004. Isolation of a 1,3-enone isomer of heptanor-41-oxoyessotoxin from *Protoceratium reticulatum* cultures. Toxicon 44, 325-336.
- Miles CO, Samdal IA, Aasen JAG, Jensen DJ, Quilliam MA, Petersen D, Briggs LM, Wilkins AL, Rise F, Cooney JM and MacKenzie AL, 2005. Evidence for numerous analogs of yessotoxin in Protoceratium reticulatum. Harmful Algae 4, 1075-1091.
- Munday R, Aune T and Rossini GP, 2008. Toxicology of the yessotoxins. In Seafood and Freshwater Toxins: Pharmacology, Physiology, and Detection", Second Ed., (Botana L. ed.), Taylor & Francis, pp. 329-339.
- Murata M, Kumagai M, Lee JS and Yasumoto T, 1987. Isolation and structure of yessotoxin, a novel polyether compound implicated implicated in diarrhetic shellfish poinoning. Tetrahedron Lett. 28, 5869-5872.
- Ogino H, Kumagai M and Yasumoto T, 1997. Toxicologic evaluation of yessotoxin. Nat. Toxins 5, 255-259.



- Pazos MJ, Alfonso A, Vieytes MR, Yasumoto T, Vieites JM and Botana LM, 2004. Resonant mirror biosensor detection method based on yessotoxin–phosphodiesterase interactions. Anal. Biochem. 335, 112-118.
- Pazos MJ, Alfonso A, Vieytes MR, Yasumoto T and Botana LM, 2005. Kinetic analysis of the interaction between yessotoxin and analogues and immobilized phosphodiesterases using a resonant mirror optical biosensor. Chem. Res. Toxicol. 18, 1155-1160.
- Pazos MJ, Alfonso A, Vieytes MR, Yasumoto, T. and Botana, L. M. 2006. Study of the Interaction between Different Phosphodiesterases and Yessotoxin Using a Resonant Mirror Biosensor. Chem. Res. Toxicol. 19, 794-800.
- Pérez-Gómez A, Ferrero-Gutiérrez A, Novelli A, Franco J-M, Paz B and Fernández-Sánchez MT, 2006. Potent neurotoxic action of the shellfish biotoxin yessotoxin on cultured crebellar neurons. Toxicol. Sci. 90, 168-177.
- Pierotti S, Malaguti C, Milandri A, Poletti R and Rossini GP, 2003. Functional assay to measure yessotoxins in contaminated mussel samples. Anal. Biochem. 312, 208-216.
- Pierotti S, Albano C, Milandri A, Callegari F, Poletti R and Rossini GP, 2007. A slot blot procedure for the measurement of yessotoxins by a functional assay. Toxicon 49, 36-45.
- Rhodes L, McNabb P, Beuzenberg V and Briggs L, 2004. Waitaria Bay G14: Yessotoxin in GreenshellTM mussels and the dinoflagellate Gonyaulax cf spinifera. Report No. 937, Cawthron Institute, Nelson New Zealand.
- Ronzitti G, Callegari F, Malaguti C and Rossini GP, 2004. Selective disruption of the E-cadherincatenin system by an algal toxin. Br. J. Cancer 90, 1100-1107.
- Ronzitti G, Hess P, Rehmann N, and Rossini GP, 2007. Azaspiracid-1 alters the E-cadherin pool in epithelial cells. Toxicol. Sci. 95, 427-435.
- Ronzitti G and Rossini GP, 2008. Yessotoxin induces the accumulation of altered E-cadherin dimers that are not part of adhesive structures in intact cells. Toxicology 244, 145-156.
- Rossini GP, Ronzitti G and Callegari F, 2006. The modes of action of yessotoxin and the toxic responses of cellular systems. In "Toxines et Cancer" (Goudey-Perrière, F., Benoit, E., Goyffon, M. and Marchot, P. ed). Lavoisier, Paris, pp. 67-76.
- Samdal IA, 2005. Yessotoxins in algae and mussels Studies on its sources, disposition, and levels. Thesis for the degree of Doctor Scientiarum. Norwegian School of Veterinary Science, Oslo 2005.
- Samdal IA, Aasen JAB, Briggs LR, Dahl E and Miles CO, 2005. Comparison of ELISA and LC-MS analyses for yessotoxins in blue mussels (*Mytilus edulis*). Toxicon 46, 7-15.



- Satake M, Terasawa K, Kadowaki Y and Yasumoto T, 1996. Relative configuration of yessotoxin and isolation of two new analogs from toxic scallops, Tetrahedron Lett. 37: 5955-5958.
- Satake M, Tubaro A, Lee J-S and Yasumoto T, 1997. Two new analogs of yessotoxin, homoyessotoxin and 45-hydroxyhomoyessotoxin, isolated from mussels of the Adriatic Sea. Natural toxins 5, 107-110.
- Suárez Korsnes M, Hetland DL, Espenes A, Tranulis M and Aune T, 2006a. Apoptotic events by yessotoxin in myoblast cell lines from rat and mouse. Toxicol. in Vitro 20, 1077-1087.
- Suárez Korsnes M, Hetland DL, Espenes A and Aune T. 2006b. Induction of apoptosis by YTX in myoblast cell lines via mitochondrial signalling transduction pathway. Toxicol. in Vitro 20, 1419-1426.
- Suárez Korsnes M, Hetland DL, Espenes A and Aune T, 2007. Cleavage of tensin during cytoskeleton disruption in YTX-induced apoptosis. Toxicol. in Vitro 21, 9-15.
- Terao K, Ito E, Oarada M, Murata M and Yasumoto T, 1990. Histopathological studies on experimental marine toxin poisoning: 5. The effects in mice of yessotoxin isolated from *Patinopecten yessoensis* and of a desulfated derivative. Toxicon 28, 1095-1104.
- Tubaro A, Sosa S, Carbonatto M, Altinier G, Vita F, Melato M, Satake M and Yasumoto T, 2003. Oral and intraperitoneal acute toxicity studies of yessotoxin and homoyessotoxins in mice. Toxicon 41, 783-792.
- Tubaro A, Sosa S, Altinier G, Soranzo MR, Satake M, Della Loggia R and Yasumoto T, 2004. Short-term toxicity of homoyessotoxins, yessotoxin and okadaic acid in mice. Toxicon 43, 439-445.
- Tubaro A, Giangaspero A, Ardizzone M, Soranzo MR, Vita F, Yasumoto T, Maucher JM, Ramsdell JS and Sosa S, 2008a. Ultrastructural damage to heart tissue from repeated oral exposure to yessotoxin resolves in 3 months. Toxicon 51, 1225-1235.
- Tubaro A, Bandi E, Sosa S, Soranzo MR, Giangaspero A, De Ninis V, Yasumoto T and Lorenzon P, 2008b. Effects of yessotoxin (YTX) on the skeletal muscle: an update. Food Addit. Contam. 28, 1-6.
- Turrini A, Saba A, Perrone D, Cialfa E and D'Amicis A, 2001. INN-CA (Nationwide Nutritional Survey of Food Behaviour). Food consumption patterns in Italy: the INN-CA Study 1994-1996. Eur. J. Clin. Nutr. 55(7), 571-588.
- Volatier J-L, 2000. INCA (Individuelle et Nationale sur les Consommations Alimentaires), Enquete INCA individuelle et nationale sur les consommations alimentaires. Agence Francaise de Securite Sanitaire des Aliments (AFSSA). Tech et Doc, Paris, 158 pages.



- WHO/IPCS (World Health Organization/International Programme on Chemical Safety). 2007. Draft guidance document on characterizing and communicating uncertainty in exposure assessment. http://www.who.int/ipcs/methods/harmonization/areas/draftundertainty.pdf
- Yasumoto T, Oshima Y and Yamaguchi M, 1978. Occurrence of a new type of shellfish poisoning in the Tohuku District. Bull. Jap. Soc. Sci. Fish. 44, 1249-1255.
- Yasumoto T, Murata M, Oshima Y, Matsumoto GL and Clardy J, 1984. Diarrhetic shellfish poisoning. In: Ragelis, E.P. (Ed.), Seafood Toxins, American Chemical Society Symposium Series, Washington DC, USA, pp. 207-214.
- Yasumoto T and Takizawa A, 1997. Fluorimetric measurement of yessotoxins in shellfish by high-pressure liquid chromatography. Biosci. Biotechnol. Biochem. 61, 1775-1777.



LIST OF ABBREVIATIONS

APHA	American Public Health Association
ARfD	Acute reference dose
ASP	Amnesic Shellfish Poisoning
AZA	Azaspiracid
AZA1	Azaspiracid 1
AZA2	Azaspiracid 2
A7A3	A zasniracid 3
Δ7Ρ	A zaspiracid Shellfish Poisoning
BTY	Brevetovin
b w	Body weight
	Adonagina 2' 5' avalia mononhagnhata
CCEED	Codex Committee for Eigh and Eighery Droducts
CCMAS	Codex Committee for Fish and Fishery Products
CCMAS	Codex Committee on Methods of Analysis and Sampling
CEN	European Committee for Standardization
	Creatinine phosphokinase
CONTAM Panel	Panel on Contaminants in the Food chain
CRL	Community Reference Laboratory
CRL-MB	Community Reference Laboratory for marine biotoxins
CTX	Ciguatoxins
DA	Domoic acid
DG SANCO	Health and Consumer Protection Directorate General
DNA	Deoxyribonucleic acid
DSP	Diarrhoeic Shellfish Poisoning
DTX	Dinophysis toxins
DTX1	Dinophysis toxin 1
DTX2	Dinophysis toxin 2
DTX3	Dinophysis toxin 3
EC	European Commission
FCVAM	European Centre for the Validation of Alternative Methods
FFC	European Economic Community
EEC	European Ecolomic Community
	Enzyme linked immunosorbent assay
	Europeen Union
	European Union East and Agriculture Organization of the United Nations
	Food and Agriculture Organization of the Onlied Nations
	Sixth Framework Programme
HPLC	High-performance liquid chromatography
HPLC-FLD	High-performance liquid chromatography-fluorescence detection
IC_{50}	Inhibitory concentration - the concentration of a substance that reduces the
	effect by 50%
IOC	Intergovernmental Oceanographic Commission of UNESCO
i.p.	Intraperitoneal
IRMM	Institute for Reference Materials and Measurements
ISO/IUPAC/AOAC	International Organization for Standardization/ International Union of Pure
	and Applied Chemistry/Association of Analytical Communities
JMPR	Joint FAO/WHO Meetings on Pesticide Residues
K _D	Equilibrium dissociation constant
LC-FLD	Liquid chromatography-fluorescence detection
LC-MS	Liquid chromatography-mass spectrometry
LC-MS/MS	Liquid chromatography-mass spectrometry/mass spectrometry
LDH	Lactate dehvdrogenase
LD_{50}	Lethal dose – the dose required to kill half the members of a tested animal
== 50	population
	r · r



LOAEL	Lowest-observed-adverse-effect level
LOD	Limit of detection
LOQ	Limit of quantification
MBÀ	Mouse bioassay
MI	Marine Institute
MS	Mass spectrometry
NOAEL	No-observed-adverse-effect level
NOEL	No-observed-effect level
NRCC	National Research Council Canada
NVI	Norwegian Veterinary Institute
OA	Okadaic acid
OJ	Official Journal of the European Union
PDE	Phosphodiesterase or 3'.5'-cyclic nucleotide 5-nucleotidohydrolase
PITX	Palvtoxins
pNPP	Para-nitrophenylphosphate
<i>p.o.</i>	Oral administration
Post-MC	Post-market control
PP1	Protein phosphatase-1
PP2A	Protein phosphatise-PP2A
Pre-MC	Pre-market control
PSP	Paralytic shellfish poisoning
PTP	Permeability transition pore
PTX	Pectenotoxin
PTX1	Pectenotoxin 1
PTX2	Pectenotoxin 2
RBA	Rat bioassay
SLV	Single laboratory validation
SM	Shellfish meat
SOP	Standard operating procedure
STX	Saxitoxin
TDI	Tolerable daily intake
TEF	Toxic equivalence factor
UK	United Kingdom
UNESCO	United Nations Educational, Scientific and Cultural Organization
UV	Ultraviolet
WG	Working group
WHO	World Health Organization
YTX	Yessotoxin
YTX eq.	Yessotoxin equivalents